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Preterm labour occurs in approximately 10 % of pregnancies and shows no signs of 
abating.  Prostaglandin E2 (PGE2) synthesis plays a regulatory role in a number of 
important processes that are necessary for successful labour.  One role for PGE2 is the 
activation of contractility in the muscle that contracts during labour, the myometrium. 
The myometrium is theorised to separate into two functional compartments during 
pregnancy and parturition.  During parturition, the fundal region contracts 
downwards, whilst the lower segment relaxes.  PGE2 binds to four G-protein coupled 
receptors, termed E-series (EP1-4), which modulate a dynamic range of responses due 
to differential binding of G proteins.  The accepted theory for the function of EP 
receptors in the myometrium, at the time of labour, is that EP1 and EP3 are pro-
contractile receptors whilst EP2 and EP4 receptors are anti-contractile.  This thesis 
studied the compartmental expression of the EP receptors and the signalling pathways 
they couple to in the pregnant myometrium.  EP receptor mRNA and protein do not 
alter in expression between sample groups, before or after the onset of labour.  
Further experiments identified EP2 receptors to activate both pro- and anti-labour 
responses (expression of COX-2 and inhibition of myometrial contractility), 
interestingly by two distinct G protein signalling pathways, questioning its role as an 
anti-labour receptor.  A novel EP4 receptor agonist also activated cell signalling 
pathways not previously associated with this receptor.  An EP3, but not an EP1, 
antagonist inhibited spontaneous and PGE2 induced contractility, despite the 
activation of similar signalling pathways.  Overall, this study indicates that the action 
of an individual EP receptor is more diverse than anticipated, indicating that the 
myometrium is a complex, dynamic system enabling efficient reprogramming of 
responsiveness during pregnancy and labour. 
Statement of originality   All  work  presented  in  this  thesis  was  performed  by  myself  unless  stated otherwise in the text.      
Table of Contents Abstract .......................................................................................................................................................2 Statement of originality.......................................................................................................................3 Acknowledgements...............................................................................................................................7 Abbreviations...........................................................................................................................................8 List of figures.........................................................................................................................................10 Chapter One ...................................................................................................................................................10 Chapter Three ...............................................................................................................................................10 Chapter Four..................................................................................................................................................11 Chapter Five...................................................................................................................................................12 Chapter Seven ...............................................................................................................................................12 List of tables...........................................................................................................................................13 Chapter One ...................................................................................................................................................13 Chapter Two ..................................................................................................................................................13 Chapter Five...................................................................................................................................................13 CHAPTER ONE ......................................................................................................................................14 Introduction...........................................................................................................................................14 INTRODUCTION...................................................................................................................................15 1.0 Parturition ....................................................................................................................................................15 1.0.1 The Myometrium.............................................................................................................................15 1.0.2 Prostaglandins ..................................................................................................................................16 1.0.3 Cyclooxygenase‐2............................................................................................................................19 1.1 G‐protein coupled receptors (GPCRs).......................................................................................21 1.1.1 Classification..................................................................................................................................21 1.1.2 Structure..........................................................................................................................................21 1.1.3 Mode of Action ..................................................................................................................................22 1.1.4 Signalling pathways .......................................................................................................................25 1.1.5 Regulation ...........................................................................................................................................29 1.2 PGE2 receptors............................................................................................................................................31 1.2.1 EP1 Receptor .....................................................................................................................................31 1.2.2 EP2 receptor ......................................................................................................................................32 1.2.3 EP3 receptors ....................................................................................................................................32 1.2.4 EP4 receptor ......................................................................................................................................32 1.2.5 EP receptors and the myometrium........................................................................................33 1.2.6 Contractility and EP receptors .................................................................................................34 1.3 Infection and Inflammation.................................................................................................................36 1.3.1 Cytokines and EP receptors .......................................................................................................36 1.4 Preterm labour...........................................................................................................................................37 1.4.1 Management.......................................................................................................................................39 AIMS.........................................................................................................................................................................41 CHAPTER TWO.....................................................................................................................................42 Materials and Methods .....................................................................................................................42 Materials................................................................................................................................................................43 Chemicals and Solvents............................................................................................................................43 Enzymes...........................................................................................................................................................44 
  5 
Miscellaneous................................................................................................................................................44 Cell Culture Materials................................................................................................................................44 Antibodies .......................................................................................................................................................45 siRNAs...............................................................................................................................................................46 Buffers and Solutions ................................................................................................................................46 Assay kits.........................................................................................................................................................47 Methods .................................................................................................................................................................48 Tissue Collection..........................................................................................................................................48 Human Myometrial Cell Culture..........................................................................................................48 Protein Extraction.......................................................................................................................................48 SDS‐PAGE and Western Immunoblotting.......................................................................................49 Immunostaining...........................................................................................................................................50 Contractility Studies ..................................................................................................................................51 Calcium Mobilisation Studies................................................................................................................52 PGE2 ELISA......................................................................................................................................................52 cAMP Assay ....................................................................................................................................................53 cDNA Synthesis ............................................................................................................................................53 Primer Design ...............................................................................................................................................54 siRNA Transfection ....................................................................................................................................54 Flow Cytometry............................................................................................................................................55 Statistical Analysis......................................................................................................................................56 CHAPTER THREE................................................................................................................................. 57 The EP2 receptor activates a positive feed‐forward loop of its ligand, PGE2, via COX‐2 activation, which is dependent upon calcium.........................................................57 3.0 Introduction.................................................................................................................................................58 3.1 EP2 receptor is present in both pre‐labour and labouring myometrial tissue samples and does not change in matched upper and lower segment biopsies................60 3.2 Spontaneously contracting lower segment myometrial strips are inhibited by the EP2 receptor agonist, butaprost. ..............................................................................................................63 3.3 The EP2 receptor couples to Gαs protein to induce cAMP..................................................65 3.4 The EP2 receptor agonist, butaprost, activates intracellular calcium in cultured myometrial cells. ...............................................................................................................................................67 3.5 EP2 receptor agonist increases COX‐2 mRNA and protein in a time and dose dependent manner...........................................................................................................................................71 3.6 Role of ERK (p42/44) in COX‐2 activation by EP2 receptor agonists. ..........................73 3.7 The membrane permeable calcium chelator, BAPTA‐AM, inhibits EP2 receptor agonist increase of COX‐2.............................................................................................................................75 3.8  COX‐2 activation functions to increase production of PGE2 that is dependent upon calcium release and simultaneous mPGES‐1 synthesis. ...............................................................78 3.9 Summary and Discussion......................................................................................................................80 CHAPTER FOUR....................................................................................................................................85 Compound 1F: A novel EP4 receptor agonist........................................................................85 4.0 Introduction.................................................................................................................................................86 4.1 Localisation and expression of EP4 receptors in myometrium is not regulated with labour status........................................................................................................................................................88 4.2 Compound 1F reduces contractility in spontaneously contracting myometrial strips........................................................................................................................................................................90 4.3 The ability of Compound 1F to activate Gαs signalling.........................................................92 4.4 EP4 receptor agonists stimulate intracellular calcium mobilisation.............................94 4.5 EP4 receptor agonist induces ERK phosphorylation but not EGR‐1 phosphorylation in cultured human myometrial cells..................................................................97 
  6 
4.6 EP4 receptor agonist sometimes stimulates cyclin‐D1 protein expression but does not effect the cell cycle...................................................................................................................................99 4.7 EP4 receptor agonist weakly stimulates β‐catenin but does not up‐regulate COX‐2, IL8 or Connexin‐43 .......................................................................................................................................101 4.8 Summary and discussion ...................................................................................................................104 CHAPTER FIVE................................................................................................................................... 108 EP3 receptors, but not EP1 receptor, mediate PGE2 induced contractions ......... 108 5.0 Introduction..............................................................................................................................................109 5.1 Nuclear expression of EP1 receptor increases significantly at the time of labour.................................................................................................................................................................................110 5.2 Expression of EP3 receptor increases in the lower segment myometrium at the time of labour ..................................................................................................................................................114 5.3 An EP3 receptor antagonist but not EP1 receptor antagonist inhibits spontaneously contracting myometrial strips ...............................................................................119 5.4 EP3 receptor agonist stimulates calcium mobilisation......................................................122 5.5 EP3 agonist inhibits cAMP in a pertussis toxin sensitive manner................................124 5.6 Four EP3 variants are translated into protein........................................................................126 5.7 EP3 variant 9 is part of the higher‐order dimer ....................................................................128 5.8 Summary and discussion ...................................................................................................................130 CHAPTER SIX...................................................................................................................................... 136 Summary Discussion ...................................................................................................................... 136 Appendix............................................................................................................................................... 143 7.0 Sample Myographs................................................................................................................................144 7.0.1 Example of EP2 receptor agonist addition on spontaneously contracting myometrial biopsies ...............................................................................................................................144 7.0.2 Example of EP4 receptor agonist addition upon spontaneously contracting myometrial biopsies ...............................................................................................................................145 7.1 Nuclear localisation analysis of pre and post labour myometrial tissue samples146 References ........................................................................................................................................... 147  
Acknowledgements   I would  like to thank Prof. Phillip Bennett  for allowing me to do my PhD in his laboratory and for the guidance he has provided throughout.  Many thanks also go  to  Dr.  Aylin  Hanyaloglu who was  always  on  hand  to  guide me  through  the maze of GPCRs.  I am also indebted to her for her time, patience and guidance in the write‐up of this project.    Members of the IRDB, old and new, for constantly lifting my spirits, and always being  on  hand  for  extended  coffee  breaks.    Particular  thanks  to  Tamsin Lindstrom, who inspired me to be a better scientist (if not a messy one!).   Sheri Lim and Shirin Khanjani, for looking after me and being great companions in the lab.   Shankari Arulkumaran and Lynne Sykes for their help and dedication with the contractility work.   Above all, I would like to thank my parents, sister and brother for all the love and guidance they have given me over the years and the continuous support  I have received.    
Abbreviations   
AC Adenylate cyclase 
ADP Adenosine monophosphate 
AH6809 EP2 receptor antagonist 
AP Action potential 
AP1 Activator protein 1 
ATP Adenosine trisphosphate 
β1-AR Beta 1 adrenergic receptor 
β2-AR Beta 2 adrenergic receptor 
Ca2+ Calcium  
cAMP Cyclic adenosine monophosphate 
CEB/P CCAAT-enhancer binding protein 
CHO Chinese hamster ovary 
COX Cyclooxygenase 
cPGES Cytosolic prostaglandin E synthase 
Cx-43 Connexion 43 
DAG Diacylglycerol  
DAPI 4'-6-Diamidino-2-phenylindole 
DNA Deoxyribonucleic acid 
EGR-1 Early growth response 1 
EIA Enzyme immunoassay  
EP Prostaglandin E2 receptor 
ERK Extracellular signal regulated kinase 
G-protein Guanine binding protein 
GAP GTPase accelerating protein 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GDP Guanine diphosphate 
GPCR G-protein coupled receptor 
GRK G-protein coupled receptor kinase 
GSK-3β Glycogen synthase kinase-3 beta 
GTP Guanine trisphosphate 
HCl Hydrogen chloride 
HEK Human embryonic kidney 293 
Hsp-90 Heat shock protein-90 
IBMX 3-isobutyl-1-methylxanthine 
IL-1β Interleukin 1β 
IL2 Intracellular loop 2 
  9 
IL3 Intracellular loop 3  
IL-8 Interleukin 8 
IL-10 Interleukin 10 
IP3 Inositol trisphosphate 
L- Pre-labour 
L+ In labour 
LH Leutinising hormone 
LPS Lipopolysaccharide  
LS Lower segment 
MAPK Map kinase kinase 
mPGES Microsomal prostaglandin E synthase 
MLCK Myosin light chain kinase 
mRNA Messenger RNA 
NF-κB Nuclear factor-kappa B 
NT Non-targeting  
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PG Prostaglandins 
PGDH 15-hydroxy prostaglandin dehydrogenase 
PGE2 Prostaglandin E2 
PGES Prostaglandin E synthase 
PI3K Phosphoinositide 3-kinase 
PI Propidium iodide 
PIP2 Phosphatidylinositol 4,5-bisphosphate 
PKA Protein kinase A 
PKC Protein kinase C 
PTL Preterm labour 
PTX Pertussis toxin 
RGS Regulators of G protein signalling 
SEM Standard error of mean 
SDS Sodium dodecyl sulphate 
TBS Tris buffered saline 
Tcf/Lef T-cell factor/leukocyte enhancing factor 
TLR Toll like receptor 
TNFa Tumour necrosis factor a 
U0126 MEK inhibitor 




 Figure 1.1.2  Structure of Class A GPCR  Figure 1.1.3  GPCR cycle  Figure 1.1.4  GPCR signalling pathways  Figure 1.4.1  Neonatal death factors  Figure 1.4.2  Incidence of retinopathy in preterm neonates  Figure 1.4.3  PTL is a multifactorial disease   
Chapter Three  Figure 3.0  Canonical EP2 receptor activation in myometrium  Figure 3.1  EP2 receptor expression in myometrial tissue, upper and lower segment, before and at the onset of labour 
 Figure 3.1  EP2 receptor agonist and its effect on myometrial contractility  Figure 3.2  Effect of EP2 receptor agonist on contractility  Figure 3.3  EP2 receptor agonist and cAMP production  Figure 3.4.1  EP2 receptor agonist and calcium mobilisation  Figure 3.4.2   EP2 receptor agonist and effect of PTX on calcium mobilisation  Figure 3.5  EP2 receptor agonist increases expression of COX‐2 mRNA in a time and dose dependent manner but does not effect Cx‐43 expression. IL‐8 mRNA increases over time  
  11 
Figure 3.6  EP2 receptor agonist phosphorylates ERK.  Inhibition of ERK phosphorylation inhibits ability of EP2 receptor agonist to increase COX‐2  Figure 3.7.1  EP2 receptor agonist induced calcium mobilisation is attenuated by BAPTA‐AM, which inhibits EP2 reeceptor agoinist induced COX‐2 expression  Figure 3.7.2  EP2 receptor agonist induced COX‐2 expression is not effected by presence of PTX.    Figure 3.8  PGE2 synthesis is increased by EP2 receptor agonist via mPGES  Figure 3.9  Proposed alternative EP2 receptor signalling pathway   
Chapter Four 
 Figure 4.0.1  Signaling mechanisms activated by PGE2 stimulation of EP4 receptors in HEK cells 
 Figure 4.0.2  Structure of Compound 1F  Figure 4.1  EP4 receptor expression in myometrial tissue, upper and lower segment, before and at the onset of labour  Figure 4.2  EP4 receptor agonist and its effect on myometrial contractility  Figure 4.3  EP4 receptor agonist and cAMP production  Figure 4.4.1  EP4 receptor agonist and calcium mobilisation  Figure 4.4.2  EP4 receptor agonist induced calcium mobilisation is attenuated by BAPTA‐AM and partially inhibited by PTX treatment  Figure 4.5  EP4 receptor agonist phosphorylates ERK but not EGR‐1  Figure 4.6  EP4 receptor agonist does not effect the cell cycle  Figure 4.7.1  EP4 receptor agonist weakly stimulates β‐catenin expression  Figure 4.7.2  EP4 receptor agonist does not significantly effect expression of COX‐2, Cx‐43 or IL‐8  
  12 
Chapter Five  Figure 5.1  EP1 receptor expression in myometrial tissue, upper and lower segment, before and at the onset of labour 



















Parturition marks the end of pregnancy, leading to expulsion of the neonate.  This occurs 
at approximately 40 weeks in humans and is synchronised with the timely development 
of the neonate.  As gestation comes to an end a series of processes are set into motion to 
ensure that the neonate is delivered effectively.  Important in this developing scheme is 
the reorganisation of the cervix from a rigid structure to a compliant one.  Successful 
parturition also entails a switch in activity of the muscle that contracts during labour, the 
myometrium, from relative quiescence to that of coordinated, fundally dominant 
contractions [7].  
1.0.1 The Myometrium  Situated between the endometrium and perimetrium the myometrium is composed of  smooth  muscle  fibres  and  made  up  of  myometrial  smooth  muscle  cells (myocytes).  The myocytes are distributed in ill‐defined layers linked by connective tissue,  interspersed with  arterial  and  venous  vasculature.    However,  this  random pattern means that  they are able  to generate  ‘a  force  in any direction’ resulting  in contractions  in  more  than  one  direction.    In  amongst  the  myocytes,  is  a  varied population  of  leukocytes  that  can  also  release  cytokines,  including  macrophages, neutrophils, large granular lymphocytes and others of the T‐cell lineage [8].   
 
It has been proposed that the myometrium is partitioned into upper and lower segments 
and that the upper segment of the uterus contracts to push the neonate down whilst the 
lower segment functions more like the cervix and relaxes during labour, allowing ease of 
passage of the neonate [9].  This divide has been extended to uterotonic components.  A 
fundus to cervix gradient has been cited for connexin 43, COX-1 and COX-2 [10-12], 






Central to parturition are prostaglandins (PGs). They regulate a broad range of 
physiological actions in almost every tissue type in the body; most cells synthesise almost 
undetectable/basal levels.  They are cyclopentane-structured fatty acids produced by the 
liberation of arachidonic acid and subsequent catalysation by cyclo-oxygenase (COX) 
synthesizing first PGG2 and then PGH2.  PGH2 is acted upon by one of a group of 
synthases that, by modification of the cyclopentane ring, produce prostaglandins (Figure 
1.0.2).  Nine synthases have been identified thereby producing nine prostaglandins – 
prostaglandin E2 (PGE2) is the focus of this thesis. 
 
  
Figure 1.0.2.  Prostaglandin Biosynthetic Pathway.  Membrane bound arachidonic acid is liberated 
by phospholipase A2.   Arachidonic acid is subsequently catalysed by cyclooxygenase (COX) 1 or 2 
resulting in synthesis of PGH2.  PGH2 is converted to one of nine prostaglandins, dependent upon 
the end synthase.   
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1.0.2.1 Prostaglandin E2  Prostaglandin  E2  is  the most  abundantly  produced  prostanoid  in  the  body  and  is involved  in  a  variety  of  biological  activities.    It  is  synthesised  by  the  action  of prostaglandin E2 synthase (PGES) which acts on cyclooxygense (COX) derived PGH2.  Two  forms  of  PGE2  synthases  have  been  reported;  microsomal  PGE2  synthase (mPGES) and cytosolic PGE2 synthase (cPGES).  Experiments show the synthases to possess  distinct  enzymatic  properties,  tissue  expression,  localisation  patterns  and function [15].    There are two mPGES isoforms, mPGES‐1 and mPGES‐2.  mPGES‐1 is a peri‐nuclear protein  induced markedly  by  pro‐inflammatory  stimuli  and  is  down‐regulated  by anti‐inflammatory glucocorticoids  [15].   The  terminal  synthases  show preferential coupling with COX [16].   The profile  induction of mPGES1 is similar  to COX‐2 [17] and co‐localisation studies show peri‐nuclear regionalisation of mPGES‐1 along with COX‐2 [18].   This  functional coupling ties  in with the  inducible nature of mPGES‐1 and COX‐2 by proinflammatory stimuli [19]. 
 mPGES‐2  is  constitutively  active  and  expressed  in  various  cells  and  tissues.    It  is synthesised  as  a  golgi  membrane  associated‐protein  that  undergoes  proteolytic cleavage of the N‐terminal hydrophobic domain, which releases the mature enzyme into  the  cytosol.   mPGES‐2  can  couple with  both  COX‐1  and COX‐2  in  response  to acute  and  chronic  inflammation,  but  appears  to  show  a  slight  preference  for  ‘co‐ordination’ with COX‐2 [20].    cPGES  is constitutively expressed and unaffected by proinflammatory stimuli [19].  It has  been  found  to be  identical  to p23,  a  co‐chaperone of heat  shock protein 90 (Hsp90) [21].  Studies have also shown Hsp90 and one of its accessory proteins, CK‐II, to modulate cPGES activity.  cPGES resides in the cytosol where it is functionally linked to COX‐1 [20]. 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PGE2 is synthesised in significant quantity by fetal membranes at the onset of labour [22,  23],  notably  in  the  amnion,  and  acts  in  a  paracrine  fashion  modulating myometrial  contractility  [24].    Specific  PGES  focussed  myometrial  studies  have consistently  observed  increased  mRNA  expression  of  mPGES‐1  in  lower  segment myometrial  tissue  [25,  26]  at  the  time  of  labour.    Astle  et  al  [26]  also  saw significantly higher levels of mPGES‐2 mRNA in labouring myometrium not found by Sooranna et al [25].  cPGES mRNA was found to be present but unaffected by labour status  [26].    Localisation  studies by Astle et  al  [26] describe  the expression of  the three PGES forms to be quite distinct also; cPGES was “diffusely located throughout the myometrium” whilst mPGES‐1 was prominently in the myometrial and vascular smooth muscle cells.  mPGES‐2, however, was detected on stromal cells surrounding the  smooth muscle  cells.    Giannoulias  et  al  [27]  showed  no  changes  in mRNA  or protein  expression  of  mPGES‐1  and  m‐PGES‐2  at  the  onset  of  labour  but  found similar  staining  patterns  as  Astle  et  al  [26].    Overall,  the  changes  observed  in mPGES‐1  transcripts  and  specific  localisation  to  myometrial  smooth  muscle  cells suggests a primary role for this end synthase, at the time of labour, in contributing to PGE2 synthesis.  
In vivo, PGE2 is unstable with a chemical half‐life of 30 s and is rapidly metabolised to  13,14‐dihydro‐15‐keto  PGE2  by  15‐Hydroxyprostaglandin  dehydrogenase (PGDH)  [28].   Expression  studies  in human gestational  tissues  show  that PGDH  is localized to the placental syncytiotrophoblast and chorionic trophoblast cells.   This expression  is  lower  in  term  and  preterm  chorion  [29].    Similarly,  in  human myometrial  samples, whilst  gestational  age had no effect on  levels of PGDH,  there was a  significant decrease  seen  in PGDH protein with  labour  in both preterm and term in labour samples [30].  COX‐2 was studied in the same sample set and did not change with either gestational age or labour status.  This implies that PGDH activity may  directly  contribute  to  the  amount  of  bioactive  PGE2  available  at  the  time  of labour, thus contributing to an increase in the number of contractions. 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Like  the  other  enzymes  in  the  PG  biosynthetic  pathway,  PGDH  is  subject  to regulation  by  cytokines.    Pomini  et  al  [31]  demonstrated  this  in  cultured  term human  villous  trophoblast  and  chorion  trophoblast  cells  where  IL1β  and  TNFα treatment  decreased  PGDH  mRNA  levels  with  the  effect  reversed  by  the  anti‐inflammatory  cytokine,  IL‐10.    Additionally,  when  pregnant  mouse  Toll‐like receptor‐4  (an  instigator  of  the  pro‐inflammatory  response)  mutants  were challenged with heat‐killed  Escherichia  coli  there was  no  change  in  expression  of PGDH  in  these mice whereas wild  type mice  exhibited  decreased PGDH  synthesis [32].  
1.0.3 Cyclooxygenase‐2 Cyclooxygenase  (COX)  is  the  rate‐limiting  step  in  PG  synthesis  and  has  been well documented for its importance in relation to preterm labour.  Three isoforms of COX have  been  identified  and  differ  primarily  in  their  kinetic  response;  COX‐1  is constitutively  expressed  in  most  tissue  types  and  is  involved  in  the  immediate production of PGE2 whilst COX‐2 is the inducible form, increasing in the presence of an  inflammatory  milieu,  and  is  seen  to  activate  longer‐term  PGE2  production. Information regarding COX‐3 is still in its early stages and disputes are on‐going as to its role and existence.  Information regarding the COX‐3 isoform suggest it may be a variant of COX‐2, existing in a different catalytic state [33] or an isoform in its own right that produces anti‐inflammatory mediators [34].  No one has yet confirmed its presence in the uterine tissues.    Given  the  importance of prostaglandins  in  regulating  labour,  targeting  the protein that  governs  their  synthesis  becomes  an  obvious  target.   The  role of  COX‐2  is  the most  consistently  associated with  labour; Mice  primed with  endotoxins  to  induce labour could be reversed following injection of anti‐sense to COX‐2 [35].  Similarly, Gross et  al  [36] demonstrated LPS  induced preterm  labour  to  increase COX‐2, but not  COX‐1.    In  this  case,  a  selective  COX‐2  inhibitor was  able  to  prevent  preterm delivery.    In  relation  to  the  human,  studies  in  the  amnion  show  COX‐2  mRNA 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expression to be 100 fold that of COX‐1 [37].  This increase is prior to labour onset [38] indicating a causative role rather than as a consequence of labour.  This ties in with  observations  that  the  amnion  is  a  major  source  of  prostaglandins  at  labour onset  [39].    In  the  myometrium,  COX‐1  mRNA  and  protein  is  unchanged  during pregnancy  [38,  40,  41]  and microarray  analysis  also  found  no  changes  in  COX‐1 expression  [42].    Human  myometrial  expression  studies  for  COX‐2  are  more ambiguous  however.    In  situ  hybridization  studies  by  Zuo  et  al  [43]  found  COX‐2 mRNA levels to decrease in labour in preterm and term labour samples.  Erkinheimo et  al  [44]  found  an  increase  in  COX‐2  up  to 15  fold  at  the onset  of  labour.    Other protein expression studies in the myometrium observed levels to be constant prior to and during  labour by both Sparey et  al  [10] and Giannoulias et  al  [30].   COX‐2 mRNA and protein  increases were once again seen with  increasing gestational age in lower segment biopsies but this increase was not significant at the onset of labour [41].  However, studies by Moore et al [45] found no such increase with gestational age or labour onset in their sample set.    
1.0.3.1 COX‐2 Regulation  Regulation  of  COX‐2  is  complex  involving  opportunities  for  influence  at  both  the transcriptional and post‐translational level [46].  The promoter contains an array of transcriptional  motifs  that  are  indicative  of  its  proinflammatory  nature;  this includes binding sites for transcription factors such as AP1, CEB/P and NF‐kappa B.      The  human  COX‐2  gene  contains  two  putative  κB  recognition  sites  within  its promoter region and these motifs play a major role in inflammatory processes, up‐regulated  by  a  diverse  group of  pro‐inflammatory  factors.   Mutation  of  these  two sites in an amnion epithelial cell line (WISH) hampered the ability of IL‐1β (a known stimulator  of  prostaglandin  production,  [47])  to  induce  prostaglandin  synthesis [48].   Additionally,  in situ binding of NF‐κB proteins to  the promoter of COX‐2 has been shown in primary human myometrial cells [49]. 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1.1 G‐protein coupled receptors (GPCRs)  GPCRs are, as the name implies, a set of receptors that transmit signals through the interaction with heterotrimeric guanine‐binding proteins (G‐proteins).   They make up  more  than  3  %  of  human  genes  and  are  the  largest  group  of  cell  surface membrane  receptors  encoded  by  the  mammalian  genome  [50].    They  are  found throughout the body and play fundamental roles in physiology and pathophysiology, which  adds  to  their  pharmacological  importance.    Almost  half  of  the  currently available pharmaceutical products are GPCR target compounds grossing $40 bn [3].  
1.1.1 Classification  The  GPCR  superfamily  has  been  divided  into  six  classes  based  on  sequence homology, the largest belonging to the rhodopsin or Class A family.  The classes are further divided into sub‐divisions and sub‐sub‐divisions based on the function of a GPCR and its specific ligand.   
1.1.2 Structure  GPCRs all share the structural motif of seven membrane‐spanning alpha helices, of a single  polypeptide  chain,  with  an  extracellular  N  terminus  and  intracellular  C terminus between three extracellular and three intracellular loops (Fig. 1.1.2).  The extracellular loops can be glycosylated post‐translationally and this is considered a global  phenomenon,  necessary  for  normal  plasma  membrane  expression  or function. 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GPCRs  have  been  difficult  to  crystalise  due  to  their  low  endogenous  levels  and instability  in  detergents.  In  2000,  owing  to  the  ability  to  obtain  high  levels  of  the functional  protein,  the  bovine  rhodopsin  receptor  was  the  first  GPCR  to  be crystallised  [51],  this was  in an  inactive  conformation meaning  that  the G protein binding could not be visualised.  It was not until 2007 that the crystal structure of β2 adrenergic receptor was published [52], followed by the structures of A2A adenosine [53], β1‐adrenergic  [54], CXCR4 chemokine  receptors  [55] and  the opsin  receptor [56].    Finally,  the active  conformation of β2‐AR was  crystallised  in 2010  revealing agonist binding to have a minor effect on the ligand‐binding pocket but to effect the 6th  transmembrane  region  [57].    Mutational  studies  have  determined  the Intracellular loop 3 (IL3), IL2 and the C‐terminus to be involved with heterotrimeric G  protein  recognition  and  binding.    Ligand‐receptor  interactions  occur  in  the transmembrane  region,  which  is  consequently  referred  to  as  the  ‘binding  pocket’ [58].   
 
1.1.3 Mode of Action  One of  the primary modes that GPCRs signal  is via  their cognate heterotrimeric G‐protein.    They  are  comprised  of  a  heterotrimer  of  α,  β  and  γ  subunits.    The  α subunit  can  associate  and  dissociate  with  the  β  and  γ  subunits  that  are  obligate 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β/γ  Ion channels, GIRK, PI3K, 
phospholipases, adenylyl cyclase    Once a ligand binds to the receptor a conformational change occurs, the G‐protein is then  recruited  and  activated,  exchanging  its  bound GDP  for  GTP.    Since  the  Gβ/γ heterodimer has a higher affinity for the GDP‐bound state of Gα  it is released from Gα‐GTP  after  receptor  activation  [59].    The  Gα  subunit,  together with  the  bound GTP, dissociates from the Gβ/γ subunits to activate the second messenger system it is associated with.  Although some GPCRs are constitutively active in the absence of a ligand, the general mode is that ligand binding accords conformational changes in the  receptor  leading  to G‐protein β/γ  subunit dissociation,  and  the  release of GDP allowing  GTP  to  bind.    Gα  or β/γ  or  both,  can  then  interact with  specific  effector molecules to modulate second messengers.   Receptors regain their resting state by ligand  dissociation  and  Gα  subunit  hydrolysis  of  GTP  to  GDP  by  the  α  subunits intrinsic  GTPase  activity  (GAP)  or  by  Regulators  of  G  protein  signalling  (RGS) proteins,  and  the  reassociation  of  Gβ/γ  subunits  to  once  again  form  the  inactive heterotrimer (Fig. 1.1.3.), [60, 61].    
Table 1.1.3.  G proteins and the general effectors 
Adapted from [3] 
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GPCRs with  basal  activity  have  access  to multiple  conformational  states.    Indeed, some  GPCRs  couple  to  a  restricted  subset  of  Gα  proteins,  while  others  couple simultaneously with different types of Gα proteins.  Gα subunits are made up of two domains; the guanine‐nucleotide binding site and the GTPase domain.  The identity of  the  guanine‐nucleotide  binding  site  determines  which  signalling  pathway  is activated; since there are approximately 20 different Gα subunits, a broad category of signalling pathways can be activated.  Based on primary sequence and functional similarities,  the  Gα subunits  are  divided  into  four  families;  Gαs,  Gαi,  Gαq/11  and Gα12/13 [50].   Other specialised alpha subunits, Gα‐  t and Gα−olf, have also been isolated.    Gα−t  is  the  subunit  of  transducin  and  is  activated  by  rhodopsin,  a photoreceptor.  Gα−olf interacts with olfactory receptors.    Ligand binding to one GPCR activates multiple molecules of G proteins.   Therefore multiple downstream signalling second messengers are also activated.  This results in an overall amplified response.    In  the case of PGE2,  ligand binding exerts effects 
Figure 1.1.3  GPCR cycle.  Agonist binding to receptor results in GTP to bind to Gα subunit, 
displacing GDP, causing dissociation of the heterotrimeric protein complex from the receptor.  Gα-
GTP and β/γ subunits are now free to activate effectors. GTPases (GAP) then bind Gα and 
accelerate hydrolysis of GTP to GDP, which deactivates Gα and causes disengagement of the 
effector.  Finally, Gα reassociates with Gβ/γ, marking the end of the cycle.  From       
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on  several  second messenger  pathways  resulting  in  a  differing  cellular  response, dependent on which receptor is bound.     
1.1.4 Signalling pathways 
 
1.1.4.1 Second Messengers  The exchange of GDP with GTP and the subsequent binding of  the Gα subunit  to a primary  effector  generates  an  increase  or  decrease  in  second messenger  signals.  Second  messengers  amplify  the  strength  of  the  signal  that  activate  downstream mechanisms.    Calcium,  inositol  phosphate  and  cyclic  AMP  (cAMP)  are  important second messenger  signalling  components  that  impart  regulatory  effects  on  many biochemical pathways.  In the myometrium the role of cAMP is associated with that of uterine quiescence in pregnancy [62], and is decreased at the onset of labour [63].  Calcium  is  essential  for  contractility,  through  its  association  with  calmodulin  to activate myosin light chain kinase (MLCK) leading eventually to a contraction [64].  Both have also been implicated in COX‐2 regulation.  The COX‐2 promoter contains cAMP response elements and  studies have  shown cAMP [65‐67] and calcium [68‐70] to modulate COX‐2 expression.    
1.1.4.2 Gαs protein pathway  Gαs proteins activate adenylyl cyclase (AC).  They catalyse the conversion of ATP to cAMP.    AC  exists  in  at  least  ten  isoforms;  nine membrane‐bound  and one  soluble.  The AC  isoforms are themselves vulnerable to regulation, aside  from Gαs and Gαi, but Gβ/γ subunits as well.  Other studies have found some distinctly to be regulated by  calcium  and  PKCs  (reviewed  in  [71]).    They  are  divided  into  four  groups depending  on  this  regulation;  Group  1 AC  (I,  III,  VIII)  increase  in  the  presence  of calcium and calmodulin, Group 2 AC (II, IV, VII) are activated by Gβ/γ subunits and PKC, Group 3 AC (V, VI) activity decreases when calcium concentrations are low and 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Group  4  AC  (IX)  is  not  regulated  by  calcium  or  Gβ/γ  subunits.    The  mRNA  of isoforms  Group  1  (I,  III,  VIII),  Group  2  (II),  and  Group  4  (IX)  is  present  in  non‐pregnant  and  pregnant myometrium  but  levels  of  Group  1  (I,  III,  VIII)  and  4  (IX) decreased  during  pregnancy  whilst  Group  2  (II,  IV,  VII)  and  3  (V,  VI)  increased, indicating a  shift  in expression of  calcium regulated  isoforms  to Gβ/γ  subunit  and PKC regulated isoforms at pregnancy [72].    cAMP  in  turn  activates  protein  kinase  A  (PKA).    There  are  a  number  of  ways  in which PKA can promote relaxation of the uterus.  The general mechanism it utilises is  by  inhibiting  myosin  phosphorylation,  calcium  entry  mechanism  and  PLC activation,  alongside  promotion  of  calcium  activated  potassium  currents  and calcium pumps [73, 74].    Gαs  activation  of  cAMP  can  be  studied  with  cholera  toxin,  which  permanently ribosylates Gαs, resulting in increased cAMP production.   
1.1.4.3 Gα i protein pathway  Adenylyl  cyclases  are  dually  regulated  by  G  proteins.   Whilst  Gαs  proteins  act  to stimulate  adenylyl  cyclase,  Gαi  proteins  act  to  inhibit  adenylyl  cyclase  [75],  thus decreasing the levels of cAMP.  Levels of Gαi protein do not alter in the myometrium, either  in pregnancy or after  the onset of  labour  [76].    In  the  laboratory, pertussis toxin  (PTX)  is  used  to  study  Gαi  protein  dependence.    PTX  inhibits  activation  of Gαi/o heterotrimers by ADP‐ribosylation modification.  Recently, a concept referred to  as  sensitization,  has  been  seen  for  adenylyl  cyclase  when  inhibited  by  Gαi receptors;  studies  have  shown  persistent  Gαi  coupled  pathways  to  act  in  a stimulatory manner.  This mechanism is thought to occur as “part of a compensatory mechanism  by  which  cell  adapts  to  chronic  inhibitory  input”  due  to  a  prolonged decrease of cAMP levels [77].   
Chapter 1 
  27 











Figure 1.1.4.  Cartoon illustrating some of the signalling pathways activated by GPCRs. A) 
Some of the main heterotrimeric G protein-mediated signalling pathways activated by GPCRs. 
Agonist binding results in activation of the associated G protein (GDP to GTP bound G protein) 
dissociation of the alpha subunit from the βγ subunits, which in turn act on distinct effectors. The 
GαS subunit activates adenylate cyclase (AC) leading to increases in intracellular cAMP, while 
Gαi  subunit inhibits AC activity, decreasing cAMP levels. The  Gαq/11 subtype of G protein 
activates phospholipase C (PLC), resulting in production of the second messengers inositol 1, 
4, 5, trisphosphate (IP3) and diacylglycerol (DAG). IP3, via its receptor, releases calcium from 
intracellular stores. Certain isoforms of βγ subunits associated with Gαi‐coupled receptors can 
also activate PLC ligand-gated ion channels resulting in an influx of extracellular calcium.   βγ 
subunits can also activate other pathways including PI3-kinase (PI3K). B) GPCRs can activate 
MAP kinase (MAPK) signalling via G protein and G protein-independent (arrestin) pathways. 
The  β‐arrestins  bind to ligand-activated and phosphorylated (e.g via a GPCR kinase (GRK)) 
receptor to uncouple receptor from its cognate G protein, resulting in G protein-signal 
desensitization, and promote receptor internalization.  β‐arrestins can also scaffold signalling 
proteins e.g. components of MAPK pathway, activating new signal pathways independent of its 
G protein signalling pathways.  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1.1.5 Regulation  Generally  several  homeostatic  mechanisms  exist  to  regulate  activated  GPCRs.  GPCRs are prone to desensitisation, which is essentially the diminution of the signal that  has  been  activated.    This  can  occur  within  seconds  to  minutes  after  agonist binding.    This  process  can  be  reversed  after  agonist  removal  and  this  process  is referred to as resensitisation.   Absolute  receptor  values  do  change  but  over  a  longer  time  course  of  between several  hours  to  days.    The  lag  in  time  is  due  to  the  requirement  of  de  novo biosynthesis of receptors.  The increase or decreases in receptor number are due to repeated exposure of ligand.  Moreover, it is the type of ligand that determines this; in most cases down‐regulation is induced by agonists and up‐regulation is induced by antagonists.  However, as is the case with GPCRs, rules are made to be broken.  In some cases it has been found that antagonists can induce down‐regulation and some agonists  the opposite effect.   These observations have opened up the  field  into the concept that GPCRs can form multiple conformations by distinct compounds.     Phosphorylation  has  been  established  as  one  of  the  specific mechanisms  of  GPCR regulation.   Biochemical purification of the cytoplasmic activity responsible for the phosphorylation  identified  a  family  of  kinases  that  preferentially  phosphorylate agonist‐occupied  receptors.    Collectively,  these  kinases  are  called  the  family  of  G protein  receptor  kinases  (GRK).    According  to  this  nomenclature,  rhodopsin receptor  kinase  is  denoted  GRK‐1,  the  originally  identified  β‐adrenergic  receptor kinase  (βARK)  is  denoted  GRK‐2,  and  other  members  of  this  family  of  protein kinases  are  numbered  sequentially  thereafter.    Six members  of  the GRK  family  of receptor kinases have been identified to date [79].  Myometrial mRNA and Western blotting expression studies show GRK‐2 presence in pregnant myometrium but not non‐pregnant  myometrium,  whilst,  GRK‐6  increases  in  expression  in  pregnant myometrium when compared to non‐pregnant myometrium [80].   The significance of these kinases is yet to be identified in the myometrium. 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GPCR  densensitisation  is  also  regulated  by  adaptor  proteins  that  ‘arrest’  signal transduction  and  are  therefore  called arrestins  [81].    cDNA  cloning  has  identified additional  proteins with  a  similar  structure,  thus  defining  a  family  of proteins  for phosphorylation‐dependent  regulation  of  GPCR  function.    Four  members  of  the arrestin family have been identified to date.  Arrestins uncouple the receptor and G‐protein and target the receptor to clathrin coated pits for internalisation.  However, arrestin can recruit multiple cytosolic proteins to their site of action on the plasma membrane  to  serve  as  ligand  regulated  scaffolds.    Therefore,  arrestins  appear  to function in an opposing manner.  On the one hand, desensitising the receptor, on the other  initiating  arrestin  mediated  signalling  [81].    An  important  feature  of  many GRKs  is  that  their  kinase  activity  is  highly  sensitive  to  the  conformation  of  the receptor  that  they  phosphorylate.    This  property  of  GRKs  facilitates  specific phosphorylation of only those receptors that are activated by ligand, whereas other receptors  present  in  the  same  cells  (but  not  activated  by  agonist)  are  not phosphorylated.  Thus, GRK‐mediated phosphorylation and regulation by arrestin is generally considered to be a paradigm for homologous desensitisation [82].  Second messenger kinases also regulate GPCR activity.  It has been shown that β2AR can  be  phosphorylated  by  cAMP  dependent  protein  kinase  A.    This  type  of phoshorylation impairs the ability of β2AR to couple to Gαs, without a requirement for  any  known  protein  cofactor  such  as  an  arrestin.    PKA  thus  acts  as  a  negative feedback mechanism.  PKA can phosphorylate β2ARs whether or not they have been activated  by  ligand,  in  contrast  to  the  preferential  phosphorylation  of  GRK‐2  of agonist‐activated  receptors.    In  addition,  phosphorylation  of  the β2AR  by  PKA  is generally  considered  to  be  a  paradigm  for  heterologous  desensitisation  because activation  of  any  other  receptor  that  stimulates  adenylyl  cyclase  can  also  activate PKA [83].    Once targeted for phosphorylation by kinases and arrestins there are two methods by which desensitisation and resensitisation occur.  This involves internalisation of 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the receptor through endocytic machinery, mainly through the presence of clathrin‐coated pits [84].    It has also been shown that endocytosis represents a method by which  GPCR  steady  state  levels  are  maintained.    Studies  with  the  β2AR  showed internalisation to involve continuous endocytosis and recycling of receptors [85].   
1.2 PGE2 receptors  PGE2  is  recognised by  four, heterotrimeric, G‐protein  coupled  receptors,  termed E series prostaglandin receptors (EP1 ‐ EP4).  Each receptor is encoded on a separate gene  [86]  and  differs  in  terms  of  structure  and  functional  role.    These,  then, determine  the  biological  effects  of  PGE2.    Pharmacological  differences  also  exist between receptor subtypes when binding their principle endogenous  ligand, PGE2.  This  is  in part  affected by  the  state of  coupling of G protein  subunits;  a G‐protein coupled EP receptor displays more affinity for PGE2 than a free uncoupled receptor.  Apart  from  the  differences  in  ligand  affinity  of  EP  receptors,  receptor desensitization  and  internalization  may  regulate  preferential  binding  through certain EP receptor subtypes.    
1.2.1 EP1 Receptor  The EP1  receptor  is  a 42 kD protein.    It  is  typically  coupled  to Gαq/11 protein as seen  by  activation  of  the  human  recombinant  EP1  receptor,  which  leads  to activation of calcium [87].  Disruption of this receptor in mice knockout studies has shown  the  predominant  phenotype  to  be  bone  formation.    Radioligand  binding assays  in  stably  transfected  human  embryonic  kidney  (HEK)  cells  showed EP1  to bind  PGE2  with  a  dissociation  constant  Kd  of  16‐25  nM  [88];  the  lowest  affinity when compared to the other receptor subtypes.  A splice variant has been reported in the rodent but no such evidence exists for a second form in the human.  The splice 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variant  did  not  differ  in  binding  affinity  for  PGE2  but  appeared  to  act  as  a  ‘sink’ receptor inhibiting downstream signalling [89].   
1.2.2 EP2 receptor  The  EP2  receptor  is  a  53  kD  protein  that  is  generically  seen  to  couple  with  Gαs protein.    It  has  been  cloned  and  expressed  from humans,  bovine,  rabbits,  rodents and several other species.  Affinity of PGE2 for EP2 receptor varies greatly between species,  for example,  the rat EP2 receptor has significantly higher affinity  for PGE2 than  human  or mouse  and  the mouse  EP2  receptor  shows  the  least  affinity.    EP2 binds to PGE2 with a dissociation constant Kd of 12.9 ‐ 13 nM depending on species [88].    
1.2.3 EP3 receptors  EP3  is  unique  in  that  there  have  been  ten  isoforms  identified  to  date  in  human tissue.  Splicing occurs at the C‐terminus on the seventh transmembrane, and varies in length from six to 59 amino acids [90].  EP3 isoforms, in general, couple to Gαi but due to alternate splicing have been found to couple to a variety of G proteins that activate other signaling pathways [91], though a contractile phenotype is primarily associated with labour in the myometrium, for this receptor [92].    
1.2.4 EP4 receptor  Like  EP2,  EP4  receptor  couples  to Gαs  protein  to  increase  synthesis  of  cAMP  but differs in PGE2 affinity, having a Kd of 0.59‐1.27 nm depending on the species [93].  EP4  receptors also  internalise  rapidly whereas EP2 does not [94],  implying a  role for EP4 in  immediate PGE2 responsive pathways.   Structural studies show the EP4 receptor  to  be  130  amino  acids  longer  than  EP2  and  this  can  be  attributed  to  a longer  third  intracellular  loop  and  C‐terminal  tail  [95].    The  C‐terminus  of  EP4 receptor  contains multiple  serine  and  theronine  residues, which  are  known  to  be 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more prone to phosphorylation events.  Rapid internalization was thought to be due to  these  serine and  threonine  sites but mutation  studies by Desai  et  al  [96]  found this not to be the case.   
1.2.5 EP receptors and the myometrium  Expression studies for EP receptors have been investigated previously by others in the myometrium but have been limited to RNA and qualitative protein studies [97‐99].  Briefly, baboon studies saw EP1 and EP3 expression to be significantly higher in the upper segment of the myometrium than the lower segment, but not to change with labour, whereas EP2 receptor expression was significantly lower in this region [100].    These  observations  fit  in  with  the  archetype  of  the  fundal  segment maintaining quiescence during pregnancy and switching to a contractile phenotype to facilitate movement of the neonate during labour.  Human studies, conducted by two independent groups, did not see these marked changes.  Specifically, Astle et al [97]  found  levels  of  EP4  to  remain  static  and  EP2  expression  to  be  higher  in  the lower  segment  whilst  EP1  increased  significantly  in  the  lower  segment  of  the labouring myometrium and some EP3 isoforms showed a decrease in expression in the pregnant myometrium, in both upper and lower segments,  which was followed by  a  further  decrease  after  the  onset  of  labour.    Grigsy  et  al  [99]  studied  fetal membranes  and  myometrial  samples  simultaneously  and  found  no  co‐ordinated expression between the two tissue types.  Like Astle et al [97] they found more EP1 mRNA  in  the  lower  segment  with  term  labour  although  they  also  observed increased expression in the upper segment.  EP3 on the other hand increased in the upper segment in labouring myometrium, unlike Astle et al., although this was not affected  by  labour  status.    An  increase  of  EP2  mRNA  in  the  upper  segment myometrium, with labour, was observed but did not reach significance.  EP4 mRNA was  higher  in  the  lower  segment,  and  expression  in  the upper  segment  increased with  the onset of  labour but was not  significant.   Both groups  concurred with  the observation  that  the  non‐pregnant  myometrium  contained  higher  levels  of  EP receptor transcripts versus the pregnant myometrium. 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1.2.6 Contractility and EP receptors  Myometrial  contractions  of  low  amplitude  and  frequency  are  present  throughout pregnancy  but  are  suppressed  by  the  actions  of  progesterone.    The myometrium changes from a relatively quiescent and poorly coordinated organ to become highly responsive to uterine agonists and able to generate the intense, high frequency, and synchronous  contractions  needed  during  labour.    In  pregnant  myometrium contractions  are  elicited  by  action  potentials  (APs).    APs  cause  depolarisation  of cells  and  this  leads  to  the  opening  of  voltage  gated  L‐type  calcium  channels, whereupon  calcium  floods  in  from  the  extracellular  space.  Contraction  and relaxation of myometrium are regulated by phosphorylation and dephosphorylation of the 20 kD light chain of myosin.  Myosin is the primary protein of smooth muscle thick filaments and is composed of two heavy chain subunits (approximately 200 kD each) and two of each type of light chain subunits (20 and 17 kD respectively).   In myometrium,  as  in  any  other  smooth  muscle,  an  increase  in  calcium  results  in activation of myosin light chain kinase (MLCK) by the calcium‐calmodulin complex.  MLCK phosphorylates the 20 kD regulatory light chain and leads to conformational changes  in  the  myosin  head,  which  allows  it  to  interact with  actin  filaments  and actin‐activated myosin ATP‐ase that results in contraction.  In human myometrium, spontaneous contractions are thought to heavily rely on this influx of calcium [101]. Relaxation  of  the  uterus  occurs  by  the  actions  of  phosphatase,  which dephosphorylate the myosin light chains. 
 
By late pregnancy gap junctions are formed and link myometrial cells together forming a 
continuous network [102].  One such gap junction, connexin-43 (Cx-43), increases before 
labour [103] and preterm labour [104].  This role was reinforced by generation of a 
mouse with an inducible Cx-43 mutant gene.  When the mutant was triggered in 
myometrial smooth muscle cells, parturition was delayed [105].  Through linking the 
cells the gap junctions provide a means of cellular communication, transferring, 
importantly in the contracting myometrium, second messengers, and allowing an arriving 
action potential to spread throughout the network rapidly.  Later experiments using a 
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double Cx-43 knockout confirmed delayed parturition in mice alongside evidence of 
reduced electrical activity in these myocytes [106].   The  uterus,  although myogenic,  can  be manipulated  pharmaceutically.    Published studies  with  the  application  of  exogenous  prostaglandins  exist  but  there  is  little consistency  in  data  generated.   Wikland  et  al  [107]  studied  contractility  on  term upper and lower myometrial laboring strips and found no differences in response to oxytocin in the two segments.   They did observe, however, PGE2 to have inhibitory effects  and  PGF2α  to  have  none  at  all  or  to  be  “slightly  stimulatory”  on  the  lower segment.  Both PGE2 and PGF2α had excitory effects on the upper segment.  Steinwall et al [108] conducted a study on non‐pregnant women to observe the effects of an EP2 receptor agonist (ONO‐8815Ly) on spontaneous and oxytocin‐induced uterine contractility.  Oxytocin was infused and the EP2 receptor agonist was intravenously administered whereupon uterine activity was measured.  The EP2 receptor agonist reduced the effects of oxytocin, suggesting it to be anti‐inflammatory but did this not reach  statistical  significance.    The  authors  concluded  this  to  be  due  to  the  low number of women recruited in the study.  Senior et al [109] used myometrial strips from pregnant women and demonstrated,  like Cao et  al  [110]  in  the porcine non‐pregnant myometrium,  that  there was  a  biphasic  response  to  PGE2  treatment.    At lower  doses  (0.14  nM)  PGE2  caused  an  increase  in  contractility  whereas  higher doses  (0.28  –  140  nM)  decreased  rate  of  contractility  in  the  myometrial  strips.  Further experiments using misoprostol (EP3 receptor agonist) and sulprostone (an EP1/3 receptor agonist) caused an increase in contractility whereas butaprost and rioprostil  (both  EP2  receptor  agonists)  inhibited  contractility.    AH6809  (EP1/2 receptor antagonist) did not affect contractility with sulprostone treatment.  On the basis  of  these  contractility  data,  it  is  suggested  that  EP3  receptors  are  the dominating EP subtype in the myometrium. 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1.3 Infection and Inflammation Labour is often characterised as an inflammatory process and there has been much debate as to whether inflammation and parturition have a causative or correlatory relationship.    Inflammation  is  typically  associated  with  increased  cytokine  and chemokine  levels  that  rouse  the  infux  of  an  immune  reaction  to  the  site;  studies have confirmed that  factors associated with  inflammation,  for example  IL‐1β,  IL‐6, IL‐8  and  other  pro‐inflammatory  cytokines  are  elevated  not  only  in  cases  of  PTL [111, 112] but also during normal term labour [113].   Nuclear factor kappa B (NF‐κB) is an inducible transcription factor seen as pivotal in its role in inflammatory responses. NF‐κB is an ensemble of homo‐ or heterodimers of the Rel family of proteins.  In eukaryotes these subunits are p50/p105, p52/p100, Rel (c‐Rel), p65 (RelA) and RelB, each encoded by its own unique gene.  Many of the stimuli  that  activate  NF‐κB  also  harbour  κB  recognition  sites  within  their  own promoters.  This holds true for pro‐inflammatory cytokines elevated in parturition, for  example,  IL‐6,  IL‐8,  TNF‐α,  GM‐CSF,  IL‐1β  and  IL‐12  [114].    This  results  in  a positive  feed‐forward  amplification  loop.    Studies  in  human  amnion  have  shown pro‐inflammatory  cytokines  and  NF‐κB  to  be  involved  in  the  regulation  of  COX‐2 [48] and murine models  showed NF‐κB  to be activated  by  surfactant protein‐A  in the myometrium and to play a role in labour [115].   
1.3.1 Cytokines and EP receptors 
 
The EP receptors contain putative binding motifs for transcription factors that are known 
to be of consequence in labour, such as NF-κB, AP1 and C/EBP.  Other studies have 
shown there to be a relationship between the application of cytokines and a regulation of 
EP receptor expression.  For example, stimulation with IL-1β in human glial cells caused 
an up-regulation of EP3 receptor protein and mRNA; NFκB and PKC inhibitors were 
able to block this induction [116].  IL-1β treated human cervical fibroblasts were found 
Chapter 1 
  37 
to increase mRNA for EP4 receptor and decrease EP1 receptor with no effect found on 




The average length of human gestation is approximately 40 weeks.  What remains 
undefined, however, is the process by which labour is activated.  For this reason there has 
been a failure to prevent the incidence of preterm labour (PTL).  PTL is defined as 
delivery before the 37th completed week of gestation and can affect up to 10 % of human 
pregnancies.  PTL rates are increasing in absolute numbers and as a proportion of all 
births in many western European countries.  The United States has also reported an 
increase of 20 % over the past 20 years, although this has been attributed in part to the 42 






Despite significant improvements in the care of preterm neonates and subsequent 
survival, these infants still account for the majority of neonatal mortality.  A recently 
published global report estimated that 27 % of four million neonatal deaths were due to 
PTL (Figure 1.4.1) [119]. 
Figure 1.4.1.  Pie chart depicting the percentage of neonatal deaths caused by 








If the infant does survive they are more likely to have long-term cognitive [120] and 
physical impairments (Figure 1.4.2) [121].  The financial burden attributed to preterm 
birth is also substantial; $15,100 per preterm infant versus $600 for a term birth [122]. 
 
PTL is a multifactorial disease (Fig. 1.4.3) and although it is more favourable to target the 
causes of PTL, this is not always possible since the aetiologies have distinct biological 
pathways [123].  Contractility represents a common pathway in PTL.  Therefore, research 
is ongoing into understanding the biochemical processes that contribute to the onset of 




Figure 1.4.2. An example of a physical impairment that is the result of PTL; As 
gestation decreases so does the incidence of retinopathy.  Adapted from [5] 
Figure 1.4.3.  PTL is a multifactorial disease.   





Current management of PTL primarily involves the use of tocolytic drugs, which target 
uterine contractility and often result in partial suppression of contractions.  Some have 
been shown to delay labour up to 48 hours, providing time for antenatal corticosteroids to 
be given, in order to promote neonate lung maturity or in utero transfer if necessitated 
[124].  However, tocolytic treatments are not always effective.    
 
Tocolytic agents are assessed by their effectiveness to decrease neonatal mortality and 
morbidity, rather than their ability to modulate contractility.  However, there is no first 
line tocolytic agent and those that are available are not reliable.  This is partially due to 
tocolytics targeting specific proteins that may not be the cause of contractions in that 
particular patient.  These include magnesium sulphate, calcium channel blockers, 
prostaglandin inhibitors (NSAIDs), oxytocin antagonists, beta-mimetics and antibiotics.  
 
Magnesium sulphate inhibits voltage-independent calcium channels extracellularly 
through suppression of a calcium influx across the cell membrane, and competing with 
calcium intracellularly, thereby inhibiting myosin light-chain kinase activity.  It is a 
favoured primary tocolytic in the US; 94 % of obstetrician-gynecologists surveyed opt for 
this method but the maternal side effects are frequent, as seen in up to two-thirds of 
treated women.  Fetal/neonatal concerns also exist but are less clear-cut [124].  
 
Calcium channel blockers act by preventing calcium re-uptake by voltage-dependent 
calcium channels.  This relaxes vascular and smooth muscle and therefore contractions.  
Nifedipine is one such blocker.  It has a more favourable side-effect profile and efficacy 
versus magnesium sulphate [124]. 
 
Prostaglandin inhibitors target the rate-limiting enzyme in their biosynthetic pathway 
COX.  As mentioned previously, there are two COX variants and the clinically used drug, 
indomethacin, targets both isoforms.  Clinical trials found side effects to be primarily 
fetal, effecting the ductus arteriosus and fetal oliguria.  This led to a restriction on 
treatment to a gestational age of less than 32 weeks because of concerns regarding fetal 
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ductal constriction.  However, subsequent studies failed to show significant association 
between gestational age and therapy and the adverse fetal effects seen previously.  As 
such, indomethacin administration has been suggested up to 34 weeks gestation [124].  
 
The oxytocin receptor is considered to be a pro-contractile receptor.  Oxytocin receptor 
antagonists compete for the oxytocin receptor blocking its activity.  Trial data mainly 
focuses on the oxytocin analogue, Atosiban.  A 2005 review by the Cochrane 
Collaboration showed that while atosiban had fewer side effects than alternative drugs, it 
was no better than placebo in the major outcomes, and in one study showed worse 
neonatal outcomes [125].  However, it has less associated side effects than ritodrine (see 
below) [126]. 
 
Beta-mimetics target the beta 2 adrenergic receptors (β2-AR).  Ritodrine is a β2-AR 
agonist that binds to the receptor and activates cyclic AMP, to stimulate a relaxatory 
phenotype.  Despite being the only FDA approved tocolytic, ritodrine use is hampered by 
its side effects; observed maternal side effects include tachycardia and ‘jitteriness’, 
frequent hyperglycemia and infrequent nausea, chest pain and shortness of breath [124].  
Beta-agonists can also pass through the placenta and yield similar side effects in the 
foetus to those seen in the mother [126].    
 
Antibiotics are the only form of management that do not target the myometrial cell 
surface.  Their use stems from the consistent association between preterm labour and 
intrauterine infection.  Multiple studies have evaluated the role of antibiotics to treat 
preterm labour without convincing results to support their use when membranes are 
intact.  With the added observation that a seven year follow-up study, for use of the 
antibiotic erythromycin, showed increased functional impairment in children in those 
treated, there is a strong recommendation against the use of antibiotics [127].    
 
The tocolytics available all have associated maternal and/or fetal side effects, which have 
to be considered carefully before administration.  There is no one outright ‘winner’ when 
it comes to primary management of preterm labour.  As such, the demand for continuing 
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research into other tocolytics exist.  PGE2 receptors present themselves as potential 
tocolytics; The synthesis of their ligand increases substantially at the time of labour and 
they have a regulatory role in modulating contractililty in the myometrium, although the 
exact mechanisms remain to be elucidated.     
 
AIMS 
• To investigate the expression of  the EP receptors  in human myometrium in term and labouring, upper and lower segment, samples.  To gain insight into potential  regionalisation  of  EP  subtypes  in  pregnancy  and  any  dynamic regulation during labour that may provide clues on their physiological role.  
• G‐protein coupled receptor signalling is comprised of a complex network of multiple  signalling  pathways  that  can  be  dynamically  regulated.    The traditional  role of EP2 and EP4 receptors  in  relaying  cAMP signaling  is  too simplistic  to  explain  the  role  of  these  receptors  in  pregnancy  given  the multple actions of PGE2.  Thus, the second aim is to elucidate the mechanisms initiated by these receptors in the pregnant myometrium.  








Materials All  chemicals  and  solvents  used  were  of  analytical  grade  and  obtained  from Abbot Labs (Queensborough); Abcam (Cambridge, UK); Abgent (San Diego, USA); Affymetrix (Santa Clara, USA); Ambion (Abingdon, UK); Amersham Biosciences/ GE  Healthcare  (Amersham,  UK);  Applied  Biosystems  (Cheshire,  UK);  Bio‐Rad (Hemel Hempstead, UK); Calibrochem (Beeston, UK); Beeston, UK Cambrex (Ioa, USA);  Invitrogen  (Paisley,  UK);  Cell  Signalling  Technology  (Danvers,  USA); Chemicon (Harrow, UK); Corning (New York, USA); DAKO (Glostrup, Denmark); Fisher  Scientific  (Loughborough,  UK);  Millipore  (Watford,  UK);  National Diagnostics  (Georgia  USA);  New  England  Biolabs  (Hitchin,  UK);  Perkin  Elmer (Massachusetts,  USA);  Pierce  (Illinois,  USA);  Promega  (Southampton,  UK); Qiagen  (Craley,UK);  Raymond  A  Lamb  (Eastbourne,  UK);  Roche  (Lewes,  UK); Santa Cruz Biotechnology (Santa Cruz, USA); Sentinel Diagnostics (Milan,  Italy); Sigma‐Aldrich (Poole, UK); Stratagene (Texas, USA); Thermo‐Scientific (Fife, UK); Vector (Peterborough, UK); VWR, (Lutterworth, UK);   
Chemicals and Solvents 30% Hydrogen Peroxide        VWR Absolute Alcohol          Fisher Scientific Acrylamide            Bio‐Rad Agarose            Invitrogen Ammonium Persulphate        Sigma‐Aldrich β‐mercaptoethanol          Sigma‐Aldrich Bovine Serum Albumin (BSA)      Sigma‐Aldrich Bromophenol Blue          Bio‐Rad Chloroform            Fisher Scientific DEPC‐Treated Water        Ambion DMSO              Sigma‐Aldrich   Ethidium Bromide          Invitrogen Ethylenediaminetetraacetic Acid (EDTA)    Sigma‐Aldrich Haematoxylin           VWR HistoClear            National Diagnostics 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Isopropanol            Fisher Scientific KCl              Sigma‐Aldrich Methanol            Fisher Scientific MgCl2             Sigma‐Aldrich NaAc 3M             Sigma‐Aldrich NaCl              Sigma‐Aldrich NaOH              Sigma‐Aldrich Sodium Acetate 3M pH5.5 (AnalaR)    Ambion TEMED            Bio‐Rad Tris Base            Sigma‐Aldrich Tris HCl            Sigma‐Aldrich Triton X‐100            Sigm‐Aldrich Tween 20            Bio‐Rad  
Enzymes DNase I (RNase‐free)        Invitrogen  
 
Miscellaneous ABC detection kit          Vector Labs BCA Protein Assay Reagent        Pierce ECL Plus Western Blotting Detection System  Amersham Biosciences Film              Amersham Biosciences Oligonucleotides          Invitrogen Skimmed Milk Powder        Marvel Superscript II First Strand Synthesis System  Invitrogen SYBR Green I            Sigma‐Aldrich TRIZOL Reagent          Invitrogen  
 
Cell Culture Materials Dulbeco’s Modified Eagle Medium (DMEM)  Sigma‐Aldrich Fetal Bovine Serum (FBS)        Sigma‐Aldrich 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L‐Glutamine            Sigma‐Aldrich Penicillin (100 U/mL)        Sigma‐Aldrich Phenol Red Free DMEM        Sigma‐Aldrich Streptomycin (50 μg/ml)        Sigma‐Aldrich Tissue Culture Plastic‐ware  Corning/Falcon/Orange Trypsin‐EDTA          Gibco Collagenase XI and 1A        Sigma‐Aldrich  
Antibodies 
Primary 
α‐tubulin (sc‐8035)          Santa Cruz Biotechnology β‐catenin (H‐102) Rabbit Polyclonal    Santa Cruz Biotechnology c‐Fos              Santa Cruz Biotechnology COX‐2              Santa Cruz Biotechnology EP‐1              Cayman Chemicals EP‐2              Cayman Chemicals EP‐3              Cayman Chemicals EP‐4              Cayman Chemicals GAPDH Rabbit Polyclonal         Abcam Lamin B (NA12)          Oncogene Research NF‐kB p65 (sc‐8008)        Santa Cruz Biotechnology Phosphorylated p65 (serine 536)      Cell Signaling  
Secondary Anti‐ mouse HRP          Santa Cruz Anti‐ Goat HRP          Santa Cruz Anti‐ Rabbit HRP          Santa Cruz Anti‐ Rat HRP           Santa Cruz  
Chapter 2 
  46 
siRNAs All from Dharmacon:  DHARMAFECT 2 transfection reagent    T‐2002‐0   ON‐TARGETplus Non‐Targeting siRNA    D‐001810‐01‐05 ON‐TARGETplus SMARTpool for RelA    L‐003533‐00‐0005  
Buffers and Solutions DAB solution  20µl  H2O2,  1ml  PBS  and  0.5ml  DAB (1mg/ml)  Cytosolic Buffer A  10mM  HEPES,  10mM  KCl,  0.1mM EDTA,  0.1mM  EGTA,  2mM  DTT,  1% (v/v)  NP‐40,  Complete  protease inhibitor tablets Krebs solution  119mM/l  NaCl,  16mM  CaCl2,  25mM NaHCO3,  14.7mM  KCl,  1.18mM/l KH2PO3,  1.17mM  MgSO4,  5.5mM Glucose, pH 7.4  Nuclear Buffer B  10mM  HEPES,  10mM  KCl,  0.1mM EDTA,  0.1mM  EGTA,  2mM  DTT,  1% (v/v)  NP‐40,  Complete  protease inhibitor tablets, 400mM NaCl  Neutral Buffered Formalin   40%  (v/v)  Formaldehyde,  282mM NaH2PO4, (NBF) 471mM Na2HPO4             (Stored at 4°C)  Phosphate Buffered Saline (PBS)    140mM NaCl, 2.5mM KCl, 1.5mM KH2PO4 pH7.2, 10mM Na2HPO4     pH7.2, 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RIPA lysis buffer  150mM  NaC,  1%  NP‐40,  0.5%  Deoxycholic acid,  0.1%  SDS,  50mM  Tris  pH  8.0  Roche Complete Protease Inhibitor Cocktail  SDS‐PAGE Buffer (10x)  250mM  Tris‐Base,  1.9M  Glycine,  1%  (w/v) SDS  Stripping Buffer (Protein)    100mM β‐Mercaptoethanol, 2% (w/v) SDS,           62.5mM Tris‐HCl pH 6.7  Western Blocking Solution    0.05% (v/v) Tween‐20, 5% (w/v) non‐fat milk in PBSA  Western Incubation Buffer    0.05% (v/v) Tween‐20, 0.3% (w/v) BSA,  Western Washing Solution    0.05% (v/v) Tween‐20, PBSA  Western Transfer Buffer    25mM Tris‐Base, 192mM Glycine, 20% (v/v) Methanol, (pH 8.3)  




Tissue Collection Ethics approval was obtained for upper and lower segment myometrial biopsies.  Tissue was collected with  informed consent  from patients at Queen Charlotte’s Hospital,  London.    Lower  segment  tissue was  obtained  from  the  lower  uterine incision at the time of Caesarean section simultaneously upper segment biopsies were  taken  using  a  cervical  punch  biopsy  instrument.    Not  in  labour  biopsies were  collected  from  patients  with  no  presentation  of  disease  or  multiple pregnancy, at elective Caesarean section at 39 weeks gestation.  Indications were previous  Caesarean,  maternal  request  or  presentation  of  breech.    In  labour biopsy indications were emergency sections due to fetal heart rate abnormalities with at least 4 cm dilatation, and no tocolytics received.      
Human Myometrial Cell Culture Pregnant,  not  in  labour,  biopsies  were  dissected  and  digested  in  phosphate buffered  saline  (PBS)  containing  15  mg/ml  collagenase  1A,  15  mg/ml collagenase X, and 50 mg/ml bovine serum albumin for 45 min at 37 °C.  The cell suspension was filtered through a cell strainer, centrifuged at 400 x g  for 5 min and the pellet resuspended and plated out in DMEM, 10 % FCS, 1 % 2 mmol/L L‐glutamine (GIBCO), 1 % 100 IU/ml penicillin‐streptomycin (GIBCO).   Cells were used between passage numbers 0 – 4.  
Protein Extraction 





Cultured cells Confluent cell monolayers were rinsed in PBS and lysed in a buffer containing 10 mM HEPES, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 2 mM dithiothreitol (DTT), 1  %  (vol/vol)  Nonidet  P‐40  (NP‐40)  and  complete  protease  inhibitor  tablets (Roche Diagnostics, Mannheim, Germany).  Cell lysates were incubated on ice for 10 min and NP‐40 added to a final concentration of 1 % (vol/vol).  Lysates were vortexed and centrifuged for 30 sec at 4 °C, 12,000 x g.   The supernatants were retained  as  the  cytosolic  protein  fraction.    The  pellets  were  resuspended  in  a buffer containing 10 mM HEPES, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 2 mM DTT, 400 mM NaCl, 1 % NP‐40 (vol/vol), and complete protease inhibitor tablets and shaken on ice for 15 min. The nuclear protein extracts were obtained in the supernatant  after  a  5  min  centrifugation  at  4  °C,  12,000  x  g.    For  whole‐cell lysates,  cells  were  lysed  in  radioimmunoprecipitation  assay/sodium  dodecyl sulfate (SDS) buffer [1 % NP‐40, 1 % Triton X‐100, 1 % sodium deoxycholate, 0.1 % SDS, 150 mM NaCl, 10 mM Tris‐HCl (pH 8.0), 2 mM NaF], incubated on ice for 15 min, and the supernatant collected after a 5 min centrifugation at 4 °C, 12,000 
x  g.  For  the  detection  of  phosphorylated  proteins,  sodium  orthovanadate  was added fresh to the extraction buffers at a final concentration of 1 mM.   Protein concentrations of all cell lysates were determined using DC protein assay reagents  (Bio‐Rad  Laboratories,  Hercules,  CA)  according  to  the manufacturers instructions.      
SDS‐PAGE and Western Immunoblotting 20–70  µg  proteins  were  mixed  with  Laemmli  sample  buffer  (1:1)  containing beta‐mercaptoethanol  (5 %),  and  boiled  for  5 min.    Protein was  separated  by SDS‐PAGE  gels  and  transferred  onto  nitrocellulose  membrane  (Amersham Biosciences,  Buckinghamshire,  UK).  The  membrane  was  blocked  in  buffer containing 5 % (wt/vol) milk powder, PBS, and 0.1 % Tween 20 for 30 min, and 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immunoblotted with primary antibody for 1–16 h in 1 % milk buffer followed by secondary  antibody  for  45 min.  Horseradish  peroxidase‐conjugated  secondary antibodies  (Santa  Cruz  Biotechnology)  were  used  with  ECL  Plus  (Amersham Biosciences)  or  Pico  Supersignal  (Pierce,  Rockford,  IL)  chemiluminescent reagents for signal detection.   To  detect  multiple  signals  from  a  single  membrane,  the  blot  membrane  was treated with a stripping buffer [2 % SDS, 62.5 mM Tris‐HCl (pH 6.7), and 100 mM 2‐mercaptoethanol] for 30 min at 50 °C, washed in PBS and Tween 20, and then preblocked  and  reprobed  with  a  different  primary  antibody.  The  levels  of cellular  GAPDH  (Santa  Cruz)  or  α‐actin  (Sigma)  were  used  as  a  control  for intersample variability, and the expression of Poll II (Santa Cruz) and α‐Tubulin (Santa Cruz) was used to confirm the integrity of nuclear/cytosolic fractionation.  
Immunostaining 
Tissue  5  µm  sections  were  cut  from  formalin  fixed  and  paraffin  wax  embedded myometrial  tissue.    Sections  were  deparaffinised  in  histoclear  and  rehydrated using serial ethanol dilutions.   Antigen retrieval was performed in 1 mM citrate buffer  and  hydrogen  peroxidase  activity  was  quenched  using  3  %  hydrogen peroxide for 15 min.  Sections were then blocked in 5 % normal goat serum and primary  antibody  (EP1  ‐4,  Cayman  Chemicals)  placed  12‐18  h  at  4  °C.    Slides were  washed  with  PBS  and  incubated  with  secondary  antibody  before  being stained  with  3,3‐diaminobendine  substrate  kit  (Zymed  Laboratories,  San Francisco,  CA),  subsequently  counter  stained  with  Ehrlich’s  Haematoxylin.  Images were  captured with  the  Lucia  6  program.    Control  experiments  for  all four receptors were conducted with the sera of the animal in which the primary antibody was raised  in, using appropriate dilutions, as well as blocking peptide experiments. Intensity of fluorescence was assessed by densitometry.   This was done  by  taking  an  identical  area measuring  5 mm x  5 mm,  in  three  individual cells  in  the  field objective.   The histogram value was obtained  for  the  red  field and statistical analyses were applied. 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Cultured cells  Cells were grown on 8‐well chamber slides.  Cells were treated and fixed using a 1:1 ratio of acetone:methonal  for 10 min or 4 % paraformaldehyde for 15 min.  Slides were then air dried and stored at ‐80 °C or washed with PBS and left until further  use,  respectively.    At  use,  cells  were  washed  with  PBS,  permeabilised with PBS‐Triton X100 (0.1 %) for 15 min and washed with PBS as before.  Cells were  blocked  (5  %  normal  goat  serum  in  1  %  TBS‐T)  and  incubated  with primary antibody diluted in blocking buffer overnight.   The next day cells were washed with PBS and incubated with FITC or ‐conjugated anti‐rabbit secondary antibody for 1 h at 21 °C.  Cells were washed with PBS and mounted, and stained with  Vectashield  (Vector  Laboratories).    Images were  captured with  the  IPlab program  using  the  Hamitasu  camera.    Fluorescence  intensity  was  measured using  the histogram  tool, which gave  densitometrical  figures.    All  images were taken using the same exposure time as well as identical black and white points.  Cells were also  confirmed  to be myocytes by  staining  for alpha  smooth muscle actin (Sigma, USA).  
Contractility Studies All  experiments  were  conducted  on  human  myometrial  biopsies  taken  with informed  consent  at  caesarean  section  at  term.    The  DMT  Myograph  800MS machine was used to assess contractility of myometrial strips.  Biopsies were cut into  5  mm  x  5  mm  strips  before  being  mounted  onto  the  Myograph  800MS.  Strips  were  placed  between  metal  clasps  attached  to  isotonic  tension transducers in individual organ baths filled with 5 ml of modified Krebs solution heated to 37°C on the apparatus and perfused with a 95 % O2 / 5 % CO2 ratio gas mixture.   They were then stretched to 4 g tension where previous experiments deduced  this  to  be  the  optimal  force  required  to  initiate  spontaneous contractions.   Experiments were  conducted after a baseline period of one hour had been observed and strips  that  contracted within 90 min were used.       The Chart software version 5.2 (PowerLab, ADI Instruments) was used to collect data from the transducers. 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The  first  parameter  analysed  was  rate  per  contraction.    This  looked  at  the number of contractions that occurred within the set  time period  in seconds (in the  majority  of  cases,  15  min/900  sec).    The  second  parameter  was  the  peak tension,  i.e.  the maximum tension achieved by each  strips  in grams.   The  third parameter was duration per contraction.  This illustrated how long a contraction lasted  in  seconds,  the  final  parameters  were  the  average  work  done  by  each contraction  and  the  total  work  done  (i.e.  energy  generated)  by  all  the contractions within a set time frame.  This was a calculation of the area under the curve  [height  (gram)  x  width  (second)  x  ½].    Statistical  significance  was determined by ANOVA, where the p value was less than 0.05.    
Calcium Mobilisation Studies Myometrial  biopsies  were  dissected,  digested  and  plated  onto  four  chamber glass bottomed dishes.   Cells were grown to confluence in 10 % FCS DMEM.  At confluence,  cells were  serum starved  in 1 % FCS DMEM overnight.   Cells were loaded with calcium sensitive Fluo‐4 Direct buffer (Invitrogen) for 30 min at 37 




80°C for analysis by ELISA.  PGE2 ELISA kit was used according to manufacturers instructions  (Biosource).    The  kits  contained  calibrated  standard,  coating antibody,  detection  antibody  and  horseradish  peroxidase  (HRP)  conjugate.    A tetramethyl  benzidine  solution  served  as  the  substrate  for  the  redox  reaction.  Activity of the enzymes was stopped by 1 M phosphoric acid and absorbance was measured at 450 nm.   
cAMP Assay Myocytes were  seeded  onto  12 well  plates  at  digestion,  brought  to  confluence and serum starved in 1 % FCS overnight before treatments started.  Prior to the experiment, cells were pretreated with isobutyl (IBMX), a PDE inhibitor, at 500 
µM for 5 min.    The experiment was terminated with the addition of 0.1 % HCl‐Triton‐x‐100 for 10 min on ice.  cAMP was measured using a competitive enzyme immunoassay and normalised to protein concentration.      
cDNA Synthesis RNA was extracted from frozen tissue biopsies using RNA Stat60 reagent.  Tissue was  homogenised  and  after  phase  separation with  chloroform,  total  RNA  from tissue was  extracted  using  isopropanol  and washed with  ethanol.  The  RNeasy MiniElute  procedure was  used  to  purify  the  retrieved RNA.    RNeasy MiniElute selectively purifies RNA molecules  longer  than 200 nucleotides ‐ 15 % of  total RNA is less than 200 nucleotides, such as 5.8S rRNA, 5S RNA and tRNAs, which are,  therefore, selectively excluded from the samples.   RNA was extracted  from cells  using  a  RNeasy  mini  kit  following  manufacturer’s  instructions.    RNA integrity  and  purity was  assessed  using  a  ND‐1000  UV‐Vis  spectrophotometer (NanoDrop Technologies).  Any genomic DNA contamination was removed using Deoxyribonuclease  I  Amplification  Grade  (Invitrogen)  using  manufacturer’s instructions.    RNA  concentration  was  also  quantified  using  a  NanoDrop  and converted  to  cDNA  by  reverse  transcription  using  “Superscript  first  strand synthesis  system  for  RT‐PCR”  (Invitrogen)  following  manufacturer’s instructions.   Quantitative RT‐PCR was conducted using the ABI‐7000 sequence detector  system  (Applied  Biosystems).  Power  Sybr‐green  Master  Mix  2X 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(Applied  Biosystems)  and  universal  PCR  conditions  recommended  by  the manufacturer were followed.  To normalise the data, samples are scaled relative to  each  other  by  the mean  of  the  set  of  valid  housekeeper  datapoints  for  that sample, each datapoint expressed as the ratio of housekeeping (HK) abundance in  the  sample  to  the average of  that HK  in  all  samples.   A datapoint  is marked invalid  if  it has statistically  inconsistent behaviour with the other HKs  in those samples with similar tissue types; the cut‐off Ct value for HKs was 20 cycles.  HK genes  used  in  this  thesis  were  L19  (a  ribosomal  protein)  and  GAPDH,  both constitutively  expressed  genes  regularly  used  in  myometrial  experiments  to normalise data [128, 129].  























































































































Flow Cytometry  Cells were grown to confluence and were serum starved overnight.   Cells were treated for 24 h and 48 h with EP4 receptor agonist (10 µM), with and without EP4  receptor  antagonist  (100  µM).    Cells  were  trypsinised  and  the  pellet 
Table 2.0  Primer sequences 
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resuspended in 500 µl ice cold 70 % ethanol overnight at 4 °C.  Fixed cells were washed  twice  with  PBS  and  resuspended  with  PBS  solution  containing  RNase (10 µg/ml) at 37 °C.  Cells were washed with pelleted and washed with PBS and stained with propidium iodide (50 µg/ml) for 10 min at 4 °C.  Stained cells were analysed  in a  fluorescence‐activated cell sort (FACSCalibur).   The percentage of cells in various phases of the cell cycle were analysed using the flow cytometry analysis software, FlowJo.  











3.0 Introduction  The pregnant uterus is theorised to maintain quiescence via a group of  ‘relaxatory’ proteins.   As labour approaches, these proteins are postulated to decrease to allow the contractile phenotype to predominate.  The uterus can also be divided into two components  on  an  anatomical  and  functional  basis.    It  is  hypothesised  that  the upper segment is quiescent during pregnancy, switching to a contractile phenotype at  labour  to  facilitate  neonate  movement,  whilst  the  lower  segment  exhibits contractures  during  pregnancy,  suppressed  by  the  hormonal  environment,  and  at labour relaxes to allow the neonate to pass through the birth canal.    
      The EP2 receptor  is classified as a relaxatory protein due to  its coupling with Gαs protein  and  therefore  stimulation  of  cAMP  (Fig.  3.0)  [95].    EP2  receptor  specific agonist  decreases  contractility  in  spontaneously  contracting  myometrial  strips 
Figure 3.0.  Canonical EP2 receptor activation in human myometrium.  EP2 receptor couples 
to Gαs protein to increase cAMP.  This leads to activation of protein kinase A (PKA) and 
subsequent phosphorylation of cAMP response element binding protein (CREB), which binds to 
cAMP response elements (CRE) via the coactivators cAMP response element binding protein-
binding protein (CBP) and p300. 
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[130],  however,  cell  signalling  experiments  have  been  limited  to  non‐pregnant myometrial  cells  and  its  ability  to  regulate  cAMP  production  [131].    Given  the dynamic  role  of  PGE2  in  pregnancy  and  labour,  and  that  an  individual  GPCR  can couple  to multiple  G‐protein  dependent  and  independent  signalling  pathways,  the signalling  mechanisms  of  EP2  receptor  activation  and  their  downstream  cellular action were investigated in pregnant myocytes. 
 3.1 EP2 receptor is present in both pre‐labour and labouring myometrial tissue 




FIGURE 3.1 (see over) EP2 receptor is expressed in both upper and lower uterine segments and does not 
change with the onset of labour.  (A) EP2 receptor expression was compared in matched lower (LS) and 
upper segments (US) of term labouring (L+) and term non-labouring (L-) myometrium.  mRNA was 
extracted and subjected to RTQ-PCR.  The housekeeping gene GAPDH was used to normalise the EP2 
mRNA levels.  Results are the mean of 5 L- and 6 L+ samples.  SEM± is indicated with an error bar.  
Protein was examined in whole tissue extracts. (B) Tissue was paraffin-embedded and (i) the specificity of 
the antibody determined by using immunohistochemsitry with polyclonal EP2 antibodies.  Replacement of 
anti-EP2 antibodies with preimmune IgG (IgG) and saturation of anti-EP2 antibodies with blocking peptides 
(BP) were used as negative controls.  (ii) Immunofluorescent analysis of EP2 was visualized with red-
fluorescent Alexa Fluor 594 dye, and α-actin was visualized with green-fluorescent Alexa Fluor 488 dye.  
Nuclei were stained with DAPI.  All images were captured with an x40 objective.  (iii) Fluoresence levels of 
receptor staining were quantitated.  These graphs represent the intensity of expression in the cytosol. (C) 
Whole tissue lysates were subjected to Western blotting and blots were scanned for densitometric 
analysis, normalized to GAPDH.  Results are the mean of 5 L- and 6 L+ samples.  Representative Western 












FIGURE 3.2.  Effect of EP2 receptor agonist on spontaneously contracting myometrial strips.  
Myometrial tissue strips were mounted onto the DMT myograph and stretched at 4 g tension.  
Spontaneous contractions were established after 90 min and agonist was added at the stated doses at 
20 min intervals.  Control chambers with equivalent volumes of vehicle control were also run 
simultaneously (n=3).  Tissue viability was examined by addition of oxytocin at the end of the 
experiment.  This ensured that any inhibition of contractions recorded was as a result of the drug used, 
and not cell death.  Any strips that did not spontaneously contract within 90 min of the experiment 
were excluded from analysis.  An ANOVA was performed along with the Bonferroni correction.  All 








FIGURE 3.3.  EP2 receptor couple to Gαs protein signalling pathways.  Primary cultures were 
grown to confluence and serum starved overnight.  Cells were pretreated with IBMX for 5 min 
and incubated with EP2 receptor agonist for 30 min.  EP2 receptor agonist specificity was also 
examined with an EP2 receptor anatagonist (AH6809).  Cells were pre-incubated with AH6809 
(100 µM) for 60 min before stimulation with EP2 receptor agonist (10 µM).  The experiment was 
terminated and lysed with 0.1 M HCl / 0.1 % Triton X-100.  cAMP was measured using an EIA 
system, n = 3.  An ANOVA was performed along with the Bonferroni correction.  * indicates p = 




cultured myometrial cells.  It  is now becoming apparent  that GPCRs can couple  to multiple G proteins, which are  thought  to provide a mechanism by which  ligand  responses  can vary between cell  types.   A consequence of receptor‐G‐protein promiscuity  is  that  it gives rise  to extreme  variability  in  the  effects  of  receptor  activation  and  therefore  requires investigation in individual cell types of the signalling pathways activated by a given GPCR.  Since the protein expression studies verified that the EP2 receptor is present not only  in both upper and  lower  segment myometrium, but also  is unchanged  in labouring samples, thus raising the question as to what additional role this receptor is  playing,  if  its  primary  role  is  as  a  relaxatory  protein.    Thus,  experiments were carried out to determine additional signalling pathways that EP2 could activate.  The  ability  of  EP2  receptor  agonist  to  activate  calcium  signalling  in  pregnant myocytes  was  first  assessed.    Cells  were  loaded  with  calcium  dye  Fluo‐4  before addition  of  EP2  receptor  agonist.    Results  (Fig.  3.4.1  A)  show  that  EP2  receptor agonist triggered rapid and transient (approximately 40 sec) calcium mobilisation.  To exclude Gαi protein coupling, since dissociation of β/γ subunits from Gαi protein coupling  are  known  to  activate  PLCβ  and  /  or  calcium  channels  and  therefore calcium  mobilisation  [134,  135],  the  next  set  of  experiments  utilised  the  Gαi inhibitor  pertussis  toxin  (PTX)  to  examine whether  the  calcium  triggered  by  EP2 receptor  agonist  was  due  to  Gαi  or  Gαq/11  coupling.    Confluent  myocytes  were incubated with PTX (200 ng/mL) and loaded with calcium dye Fluo‐4 (Fig. 3.4.2 A).  The presence of PTX did not inhibit EP2 receptor agonist induced calcium response but caused a slight augmentation of calcium release when EP2 receptor agonist was added.  Thus it can be concluded that calcium mobilisation by EP2 receptor agonist is not due to Gαi coupling. 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FIGURE 3.4.1  EP2 receptor agonist stimulates calcium mobilisation and c-Fos phosphorylation in 
myocytes.  Myocytes cultures were loaded with calcium sensitive dye, Fluo-4, before stimulation 
with EP2 receptor agonist and calcium was determined by confocal microscopy.  The addition of 
stimulus is indicated by an arrow.   (A) Cells were treated with 1 µM and 10 µM EP2 receptor 
agonist.  (B) Snapshot of calcium loaded myocytes treated with and without EP2 receptor agonist 





FIGURE 3.4.2.  Effect of pertussis toxin (PTX) on EP2 receptor agonist stimulated intracellular 
calcium release.  Primary cells were loaded with calcium sensitive Fluo-4 before stimulation with EP2 
receptor agonist (10 µM).  Calcium was determined by confocal microscopy.  The addition of stimulus 
is indicated by an arrow.  In PTX experiments, cells were pre-incubated with PTX overnight (200 
ng/mL).  (A) Addition of EP2 receptor agonist (10 µM) caused an immediate increase in calcium.  
Pretreatment with PTX augmented the effects of EP2 receptor agonist.  Shown here is a 





dependent manner.    It  is  accepted  that  COX‐2  is  vital  in  parturition,  although  reports  are  conflicting about  the  increase  in  protein  in  the  labouring  myometrium  [10,  30,  43,  44],  its presence,  however,  is  undisputed.    As  EP2  receptor  activation  results  in  calcium mobilisation, which is considered a pro‐labour response, it was postulated that this then  might  regulate  the  activity  of  pro‐labour  factors,  such  as  COX‐2.    Using  this potential  link,  the next  set of  experiments were  conducted  to  see what effects  the EP2  receptor  agonist,  butaprost, may  have  on  the  expression  of  COX‐2  in  human cultured  myocytes.    Initial  experiments  treated  cultured  myocytes  with  EP2 receptor  agonist  (1  µM  –  50  µΜ)  and  protein  was  extracted  at  6  h  (Fig.  3.5  A), showing COX‐2 to increase in a dose‐dependent manner.  COX‐2 expression peaked at 10 µΜ and this dose was used in all future experiments.  Changes in COX‐2 were then  measured  over  time.    Stimulation  of  primary  myocytes  with  EP2  receptor agonist (10 µΜ) induced striking increases of COX‐2 protein and mRNA at 6 h (Fig 3.5 B and C).  Further experiments analysed the expression of pro‐inflammatory factors connexin‐43 (Cx‐43) and interleukin 8 (IL‐8) since their expression is synonymous to COX‐2 and both have been shown to increase in term and preterm labour [129].  Fig 3.5 D shows  that  Cx‐43  mRNA  was  not  effected  by  EP2  receptor  agonist  stimulation.  Although  IL‐8  mRNA  levels  displayed  a  trend  to  increase  over  time  with  EP2 receptor agonist stimulation the results were not significant (Fig. 3.5 D). 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FIGURE 3.5.  Effect of EP2 receptor agonist on pro-labour factors in primary uterine myocytes.  
Cells were serum starved and confluent cultures of myocytes were (A) incubated with increasing 
doses of EP2 receptor agonist (EP2R Ag.,) for 6 h.  Whole cell protein was extracted and run with 
SDS-PAGE for Western blotting.  Membranes were immunoblotted with COX-2.  Results show 
COX-2 was stimulated in a dose responsive manner.  EP2 receptor agonist was incubated over time 
and (B) mRNA and (C) protein was extracted.  Expression of COX-2 peaked at 6 h.  (D) EP2 
receptor agonist (10 µM) did not significantly or consistently effect transcript expression of connexin-
43.  Interleukin-8 displayed a trend to increase over time.  Shown here are representative 









FIGURE 3.6.  Effect of EP2 receptor agonist on ERK activation.  (A) Primary uterine 
myocytes were serum starved and treated with EP2 receptor agonist (EP2R Ag.) over time.  
ERK phosphorylation occurs at 5 min and 15 min (n = 4).  (B) EP2 receptor agonist (10 µM) 
induced COX-2 protein was attenuated in the presence of a MEK inhibitor, U0126.  Cultures 
were pretreated with U0126, for 2 h, and then treated with EP2 receptor agonist for 6 h.  
Shown here is a representative experiment (n = 3). An ANOVA was performed along with the 










FIGURE 3.7.1.  EP2 receptor agonist stimulates COX-2 synthesis via intracellular calcium.  Primary uterine 
myocytes were loaded with calcium sensitive Fluo-4 before stimulation with EP2 receptor agonist.  In control 
experiments, cells were pretreated with BAPTA-AM (10 µM), for 30 min before being loaded with Fluo-4.  
Calcium was determined by confocal microscopy.  The addition of stimulus is indicated by an arrow. (A) 
Addition of EP2 receptor agonist (10 µM) caused an immediate increase in calcium.  Pretreatment with 
BAPTA-AM significantly decreased the effects of EP2 receptor agonist on intracellular calcium release.  (B) 
Primary uterine myocytes were grown to confluence and pre-incubated in the presence of cell permeable 
calcium chelator, BAPTA-AM (10 µM), for 30 min.  Cells were treated with EP2 receptor agonist (10 µM) for 6 
h.  Whole cell lysate was extracted and run on SDS-PAGE before being immnoblotted with COX-2.  The 
housekeeping protein GAPDH was used as a loading control.  Shown here is a representative experiment, (n 






FIGURE 3.7.2.  Effect of pertussis toxin (PTX) on EP2 receptor agonist stimulated COX-2 
production.  Primary cells were loaded with calcium sensitive Fluo-4 before stimulation with EP2 
receptor agonist (10 µM).  Calcium was determined by confocal microscopy.  The addition of stimulus 
is indicated by an arrow.  In PTX experiments, cells were pre-incubated with PTX overnight (200 
ng/mL).  (A) Addition of EP2 receptor agonist (10 µM) caused an immediate increase in calcium.  
Pretreatment with PTX augmented the effects of EP2 receptor agonist.  (B) Primary cells were grown 
to confluence and pre-incubated with PTX overnight.  Cells were treated with EP2 receptor agonist (10 
µM) for 6 h.  Whole cell lysate was extracted and run on SDS-PAGE before being immunoblotted with 
COX-2.  PTX pre-treatment did not inhibit EP2 receptor agonist induced COX-2 protein expression.  
The housekeeping protein GAPDH was used as a loading control.  Shown here is a representative 









FIGURE 3.8.  PGE2 synthesis is increased with EP2 receptor agonist via mPGES-1.  (A) 
Myocytes were serum starved overnight and were pretreated with BAPTA-AM for 30 min and 
treated with EP2 receptor agonist (10 µM) for 6 h.  Whole cell protein was extracted and assessed 
by SDS-PAGE.  mPGES-1 expression increased at 6 h in the presence of EP2 receptor agonist 
but this increase was inhibited in the presence of the BAPTA-AM (10 µM).  GAPDH served as a 
loading control.  (B) Primary uterine myocytes were serum starved overnight and treated with and 
without EP2 receptor agonist (10 µM) in the presence of the calcium chelator, BAPTA-AM (10 
µM).  Supernatant was then collected after 18 h and assessed with PGE2 EIA.  Preincubation with 
BAPTA-AM caused a substantial inhibition of PGE2 production in the presence of EP2 receptor 




3.9 Summary and Discussion  The signalling capacity of many GPCRs  is now recognised to be substantially more complex  than  initially  thought.    Thus,  the  traditional  analysis  of  single  GPCR‐mediated  secondary  messengers  for  early‐stage  drug  discovery,  such  as  the measurement  of  calcium  or  the  formation  of  cAMP,  may  not  provide  all  of  the relevant signalling information about a target receptor.  EP2  receptors  were  first  described  to  couple  to  Gαs  proteins,  which  stimulates adenylyl  cyclase  activity  to  raise  intracellular  levels  of  cAMP  [95].    In  the  uterus, cAMP  is  a  major  second  messenger  leading  ultimately  to  relaxation  of  the myometrium by activation of PKA, which in  turn  inhibits  the contractile apparatus and blocks calcium mobilisation [62].   This was confirmed in this study where EP2 receptor, activated by butaprost, increased cAMP levels and inhibited spontaneous contractions.    The work  described  in  this  chapter  demonstrates  for  the  first  time that the EP2 receptor is potentially coupled to Gαq/11 protein signalling mechanism and  therefore  activates  a  calcium  signalling  pathway, most  likely  via  activation  of IP3 receptors on intracellular calcium stores.  This signalling mechanism in turn up‐regulates expression of COX‐2.    An association between COX‐2 regulation and calcium has been reported before  in other  systems:  calcium  induced  COX‐2  via  the  regulation  of  tyrosin  kinase  in mesangial cells was confirmed with the use of ionomycin (a calcium ionophore) and thapsigargin  (a  calcium  ATPase  inhibitor)  [69],  while  BAPTA‐AM  was  utilized  to confirm that urothelial stretch and the subsequent induction of COX‐2 was calcium dependent  [70].   However, what has not been previously  shown  is  the  interaction between  EP2  receptor,  calcium mobilisation  and  COX‐2  regulation  in  any  system including myometrium.    The  data  also  demonstrates  that  EP2  receptor  activation can  induce COX‐2  synthesis via ERK phosphorylation.   There  is  also evidence  that cAMP regulates COX‐2 in other systems [65‐67], further enforced by the presence of cAMP response element motifs (CRE)  in the COX‐2 promoter of most species.   Our 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data does not exclude a role for cAMP in EP2 receptor mediated COX‐2 regulation in the  myometrium  but  does  show  that  calcium  is  essential.    An  alternative  cAMP target protein, exchange protein activated by cAMP (Epac), has been shown to play a role in calcium mobilisation [139‐141].  The kinetics of the calcium response elicited by EP2 receptor agonist is similar to other Gαq/11 associated receptor mechanisms such as the oxytocin receptor [142]; a sharp burst of activity followed by a rapid fall.  However,  the  calcium  kinetics  seen  in  response  to  Epac  agonists  [143,  144]  are typically  slower  to  rise  and  longer  lasting,  therefore  differing  from  those  seen  in typical Gαq/11 induced calcium responses, and those described here in response to EP2  receptor  activation,  allowing  us  to  exclude  a  potential  calcium  response  via Epac proteins.  Of note is the capacity which EP2 receptor activation was able to increase cAMP in myocytes.    The  levels  of  cAMP  generated  are  not much more  than  those  of  non‐treated cells.  In non‐pregnant samples, Asboth et al [131] showed that 1 µM of EP2 receptor agonist (butaprost) was able to induce cAMP formation approximately 15 fold  relative  to  their  control whereas 10 µM treatment of EP2  receptor agonist  in our  pregnant  cells  only  induced  a  change  of  approximately  1.5  times  relative  to control.   This  ties  in with observations  by Europe‐Finner et  al  [63] who  found an increase  in  Gαs  protein  levels  and  activity  in  human  myometrium  at  term  and preterm and a decrease at the onset of labour.  Therefore, perhaps a decrease in Gαs protein coupling, due to decreased levels of Gαs proteins, may allow EP2 receptor to switch  to  calcium  signalling  pathways  at  the  onset  of  labour.    Comparisons  with Asboth’s data regarding the concentrations of cAMP cannot be made since they do not state the cAMP concentration but the fold change relative to control.  If cAMP is already high then perhaps EP2 receptor activation could not appreciatively increase further activation.  Activation of Gαi protein may also mobilise calcium via association of the Gβγ with PLCβ and / or calcium channels [134, 145].  Our data showed a lack of sensitivity to 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PTX, which ‘locks’ Gαi protein in its inactive GDP‐bound form via ADP ribosylation [146],  demonstrating  that  the  EP2  receptor mediates  a  non‐Gαi mediated  calcium response.   In fact, PTX pre‐treated cells responded to EP2 receptor agonist with an augmentation of the calcium response.  This could be due to constitutive activation of  Gαi  protein,  via  other  Gαi  coupled  GPCRs  present  in  myocytes,  which  may negatively  regulate EP2‐induced calcium signalling.   Nonetheless,  as  far as we  are aware,  this  apparent  inhibition of  calcium by Gαi protein has not previously been reported.    EP2  receptor  stimulation  has  been  shown  to  promote  calcium  responses  in astrocytes  via  activation  of  the  adenylyl  cyclase  pathway  [144].    However,  in  this study the investigators inhibited extracellular calcium with EGTA and proposed the mobilisation  to  be  due  to  adenylyl  cyclase  rather  than  an  association  of  EP2 with Gαq/11 signalling.  Additionally, the calcium kinetics differed from myocytes with a slower rate of onset and a more sustained calcium response that  is  indicative of a potential Gαs/Epac mediated response, or activation of a calcium channel as it relied on extracellular calcium, and not a Gαq/11 linked receptor.     The physiological role of the dual coupling of EP2 receptor in human myometrium is intriguing;  it  was  previously  thought  that  the  only  role  for  EP2  receptor  in myometrium  is  to  mediate  relaxation  via  cAMP.    It  might  be  expected  that  EP2 receptor  expression would  increase  in  the  lower  part  of  the  uterus  at  the  end  of pregnancy  since  this  part  of  the  uterus  is  thought  to  relax  during  labour,  and decrease  in  the  contractile  fundal  region.    However  we  found  no  differences  in expression  between  upper  and  lower  segment,  or  before  and  after  the  onset  of labour.  The endogenous ligand of EP2 receptor, PGE2, is a stimulator of contractions of  the  myometrium  both  in  vivo  and  in  vitro  (Chapter  5).    This  is  presumably because,  although EP2  is  expressed  in myometrium,  the effect of PGE2 upon other co‐expressed EP  receptors  (EP‐1  and EP‐3)  overrides  the  inhibitory  effect  of  EP2 receptor.    Therefore  although  an  EP2  specific  agonist,  butaprost,  alone  causes myometrial  relaxation,  in  the physiological  setting EP2  receptor activity would be 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over‐ridden  due  to  the  powerful  pro‐contractile  effect  of  PGE2  via  EP3  receptor.  This would also be consistent with down‐regulation of Gαs proteins at  the time of labour.    However,  EP2  still  has  a  dual  role  in  labour  by  activation  of  COX‐2  by  a distinct G protein pathway.  It is therefore possible that the up‐regulation of COX‐2 by  EP2  receptor  via  Gαq/11  coupled  calcium  mobilisation  is  the  more physiologically  important  EP2  receptor‐signalling  pathway  at  term,  or  in  labour.  EP2  receptor  may  act  to  provide  a  ‘positive  feed‐forward‐loop’  in  which  PGE2 initially  derived  from  other  tissues  such  as  the  amnion,  leads  to  up‐regulation  of COX‐2  and  synthesis  of  further  PGE2  via  EP2  receptor  in  myometrium  itself,  so augmenting and amplifying the processes of labour (see model, Fig. 3.9).  This may be  particularly  important  since  COX  enzymes  have  been  described  to  have  a ‘suicidal’ nature undergoing destruction after a limited number of reactions, having a  short  half‐life  and  requiring  on‐going  re‐synthesis  during  labour  [147].  Alternatively,  it could be postulated that there  is a switch  in G protein coupling of the  EP2  receptor  towards  the  onset  of  labour,  from  Gαs  to  Gαq/11  coupling, influenced  by  the  increase  in  PGE2  concentration  at  term;  an  ‘agonist‐induced switch’.  Switches in G protein coupling due to a change in ligand concentration have been observed before; the ability of leutinising hormone (LH) receptor to stimulate calcium  is  higher  in  the  presence  of  nanomolar  concentrations  of  LH  leading  to ovulation,  however,  when  concentrations  are  in  the micromolar  range,  there  is  a switch from Gαs coupling to Gαq/11 [148].  In  summary,  the  data  generated  here  demonstrates  an  additional  signalling mechanism  for  EP2  receptor  in  the  smooth muscle  cells  of  the  uterus  leading  to Gαq/11  protein  mediated  calcium  release,  up‐regulation  of  COX‐2  and  increased synthesis of its own ligand PGE2 (Fig. 3.9).   There is an important pharmacological consequence  of  these  findings.    The  accepted  role  of  EP2  receptor  in  mediating myometrial  relaxation  has  lead  to  suggestions  that  EP2  receptor  specific  agonists might be used clinically to inhibit myometrial contractions in the context of preterm labour.  However our data suggests that, whilst EP2 receptor agonists might lead to a  brief  period  of  inhibition  of  contractions,  there  is  a  risk  that  the  associated 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Figure 3.9.  A model for EP2 receptor signalling and action in pregnant myometrium.  EP2 
receptors activate a relaxatory phenotype through Gαs coupling, resulting in cAMP formation.  
Additionally, EP2 receptors promote a contractile phenotype through their coupling to Gαq/11 proteins.  
This mobilises intracellular calcium, which increases COX-2 expression and PGE2 synthesis in human 








4.0 Introduction  Like the EP2 receptor, the EP4 receptor is coupled to Gαs.  As such, it is regularly grouped with EP2  receptor when comparisons are being made  in  terms of  cell signalling mechanisms.   It differs from EP2 receptor most notably by the length of its C‐terminal tail.  It is 108 amino acids longer and has been linked to its rapid desensitisation and internalisation patterns.  Constitutive activity in the absence of ligand, for EP4 receptor, has also been reported [94].   What  is  less well  known  about  EP2  and  EP4  receptors  is  that  their  signalling potential can be extended beyond the traditional cAMP activated pathways.  For example,  EP2  and  EP4  receptor  have  been  shown  to  stimulate  the phosphorylation  of  glycogen  synthase  kinase‐3  (GSK‐3)  and T  cell  factor  (Tcf) transcriptional  activation  in  HEK  293  cells  stably  expressing  these  receptors [149].   The mechanism by which  both  receptors  caused  this  differed  however.  EP2  was  seen  to  act  through  a  PKA‐dependent  pathway  whereas  EP4  effects were  mediated  through  a  phosphatidylinositol  3‐kinase  (PI3K)  dependent pathway.   
     Figure 4.0.  Signalling mechanisms activation by PGE2 stimulation of EP4 receptor in HEK cells.  Adapted from [1]. 
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Fujino  et  al  [1]  propose  that  this  PI3K  pathway  activates  Akt  kinase,  which phosphorylates  GSK‐3α,  resulting  in  release  and  consequent  stabilisation  and accumulation of β‐catenin and  its  subsequent  translocation  from  the  cytosol  to the  nucleus.    Once  inside  the  nucleus  β‐catenin  binds  to  Tcf/Lef  transcription factor  motifs  to  up‐regulate  the  expression  of  COX‐2.    Simultaneously,  ERK activated by EP4 regulates  the expression of a different subset of proteins (Fig. 4.0).  EP4 receptor activation has also been shown to mediate some of its actions via Gαi  proteins  [150]  and more  recently  has  been  linked  to  β‐arrestin  signalling [151].    A  study  compared  a  panel  of  EP4  receptor  agonists  and  the  responses elicited by each in HEK cells via Gαs, Gαi and β‐arrestin signalling mechanisms.  Interestingly,  this  study  found  conformational  changes  to  be  linked  to  each agonist and the activation pathways to be biased towards Gαi protein signalling mechanisms rather than Gαs protein.  More than half of these compounds tested also  favoured β‐arrestin  recruitment  versus  Gαs  protein  activation.    PGE2 was the most  potent  at  activating  Gαs  coupled mechanisms  in  EP4  receptor  stably transfected cells [152].  In  collaboration with GlaxoSmithKline  (GSK),  a novel EP4 agonist – Compound 1F  –  was  provided  to  characterise  the  signalling  properties  elicited  by  this compound in pregnant human myometrium.  Compound 1F (Fig. 4.0.1) has a pKi of 7.4 nM in membranes of Chinese Hamster Ovary cells transfected with an SFV‐1  RNA  construct  containing  the  human  EP4  receptor.    Compound  1F  was developed for the treatment of neuropathic pain, colon cancer, migraine and for increasing latency of HIV infection.  Thus in this study its potential as a tocolytic in pre‐term labour management was investigated.  
  




regulated with labour status  Initial studies  focussed on the expression of  the receptor mRNA and protein  in myometrial tissue biopsy specimens collected from women undergoing elective Caesarean  section  either  before,  or,  at  the  onset  of  labour,  in  both  upper  and lower segments.    As EP4  receptor  is Gαs  coupled  it was postulated  that  its  expression would be highest in the upper segment during pregnancy, but with the onset of labour to be more  highly  expressed  in  the  lower  segment,  as was  predicted  for  the  EP2 receptor.   Results obtained by quantitative RT‐PCR studies show that the levels of EP4 receptor mRNA decrease  in  the  lower segment with the onset of  labour but do not reach significance (p = 0.06).   Expression in the upper segment does not  change  with  labour  status  (p  =  0.79;  Fig.  4.1.  A).    Overall  EP4  receptor expression  appeared  to  be  higher  in  the  upper  segment  versus  the  lower segment but, again, there were no labour associated differences in expression (p 
= 0.79  and p  =  0.25  respectively).    The  level  of  EP4  protein was examined  via Western blotting and immunofluorescence (Fig. 4.2C); EP4 receptor protein did not  significantly  change  in  expression  between  upper  and  lower  segment  or before and after the onset of labour.  Interestingly, immunofluorescence staining of EP4 receptor (Fig. 4.1B) exhibited predominant peri‐nuclear expression with labour, as opposed to cytoplasmic distribution prior to labour.   
      
FIGURE 4.1 (see over) EP4 receptor is present in both pre and labouring myometrial tissue samples, 
and in both upper and lower segment  (A) EP4 receptor expression was compared in matched lower 
(LS) and upper segments (US) of term labouring (L+) and term non-labouring (L-) myometrium.  
mRNA was extracted and subjected to QRT-PCR.  The housekeeping gene GAPDH was used to 
quantify the relative abundance of the EP4 receptor.  Results are the mean of 5 L- and 6 L+ samples.  
SEM± is indicated with an error bar.  A Mann-Whitney test was applied and differences were 
considered significant at p = <0.05.  Protein was examined in tissue extracts. (B) Tissue was paraffin-
embedded and (i) the specificity of the antibody determined by using immunohistochemsitry with 
polyclonal EP4 antibody.  Replacement of anti-EP4 antibody with preimmune IgG (IgG) and saturation 
of anti-EP4 antibody with blocking peptides (BP) were used as negative controls.  (ii) 
immunofluorescent analysis for EP4 was visualized with red-fluorescent Alexa Fluor 594 dye, and α-
actin staining was visualized with green-fluorescent Alexa Fluor 488 dye.  Nuclei was stained with 
DAPI.  All images were captured with a x40 objective.  (iii) Intensity of receptor expression was 
analysed by measuring level of fluorescence (n=3).  (C) Whole tissue lysates were subjected to 
Western blotting and blots were scanned for densitometric analysis, and normalised to GAPDH.  










FIGURE 4.2. The effect of a novel EP4 receptor agonist on spontaneously contracting 
myometrial strips.  Myometrial tissue strips were mounted onto a DMT myograph and stretched 
at 4 g tension.  Spontaneous contractions were established after 90 min and agonist was added 
in log doses at 20 min intervals.  Control chambers with equivalent volumes of vehicle control 
were also run simultaneously (n=3).  Tissue viability was examined by addition of oxytocin at 
the end of the experiment.  Any strips that did not spontaneously contract within 90 min of the 
experiment were excluded from analysis.  An ANOVA was performed along with the Bonferroni 
correction.  Total work done showed significant decreases in spontaneous contractions at 10-5M 










FIGURE 4.3  EP4 receptor activation with Compound 1F does not exhibit coupling to a Gαs 
signalling mechanism.  Primary cultures were grown to confluence and serum starved 
overnight.  Cells were pretreated with IBMX for 5 min and incubated with Compound 1F 
(EP4R Ag.) for 30 min.  The experiment was terminated and lysed with 0.1 % HCl / Triton X-
100.  cAMP was measured using an EIA system (n=5, Mann-Whitney test, p = >0.05). 
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 FIGURE 4.4.1.  Effect of Compound 1F and EP2 receptor agonist on calcium mobilisation in 
myocytes.  Myocytes cultures were loaded with calcium sensitive Fluo-4 before stimulation 
with Compound 1F and calcium was determined by confocal microscopy.  The addition of 
stimulus is indicated by an arrow.   (A) Cells were treated with 10 µM Compound 1F.  (B) 
Cells were treated with 10 µM EP2 receptor agonist.  A representative experiment is shown 






FIGURE 4.4.2. Compound 1F induced calcium mobilisation is attenuated in presence of 
BAPTA-AM and partially inhibited by presence of pertussis toxin (PTX) in myocytes.  Myocyte 
cultures were loaded with the calcium dye Fluo-4 prior to stimulation with Compound 1F.  
Calcium was determined by confocal microscopy.  The addition of Compound 1F is indicated 
by an arrow.  Cells were pre-treated with 10 µM BAPTA-AM before stimulation with 
Compound 1F (10 µM).  Cells were pre-treated with 200 ng/ml of PTX overnight prior to 









FIGURE 4.5.  ERK is phosphorylated by Compound 1F.  Primary cell cultures were 
serum starved overnight and treated with Compound 1F (10 µM).  Whole cell lysates 
were extracted and subjected to Western blotting for protein analysis.  Protein was 
normalised to GAPDH  (A) ERK is phosphorylated with Compound 1F (10 µM) at 5 and 
15 min.  (B) Compound 1F has no effect on EGR-1 expression.  (C) Treatment with 
Compound 1F for 6 h show increased cyclin D1 protein expression in some patients 








Treatment Stage of cell cyle Gated Percentage 
Non Treated G0/G1 86.68 
 S phase 4.13 
 G2/M 9.10 
    
24 h G0/G1 88.43 
 S phase 2.92 
 G2/M 8.47 
    
24 h + Antagonist G0/G1 90.54 
 S phase 2.26 
 G2/M  6.89 
   
48 h G0/G1 89.89 
 S phase 2.98 
 G2/M 6.92 
    
48 h + Antagonist G0/G1 90.46 
 S phase 4.01 
 G2/M 5.47  
FIGURE 4.6.  Compound 1F does not impact on cell cycle.  Primary cell cultures were treated 
with Compound 1F (10 µM) for 24 h or 48 h with or without a specific EP4 receptor antagonist 
and media / treatments replenished at 24 h.  The DNA was stained with propidium iodide and 
cells analysed by flow cytometry. (A) Cells containing G0/G1 DNA, S-phase, or G2/M DNA are 
indicated by bars.  (B) The table shows treatments and percentage of cells in each stage of the 









      FIGURE 4.7.1. β-catenin changes are seen in immunofluoresence.  Primary cell cultures 
were treated with Compound 1F (10 µM) over time and (A) nuclear / cytosolic fractions 
were extracted.  There is an increased presence of β-catenin at 15 min, which falls to basal 
levels at 60 and 360 min.  α-tubulin and lambin-B were used to show clean fractionation.  
(B) Immunofluoresence was also employed.  Primary cell cultures show increased nuclear 







FIGURE 4.7.2.  Affect of Compound 1F on pro-labour factors in primary cell culture.  
Confluent cultures of myocytes were incubated with Compound 1F (EP4R Ag; 10µM).  (A) 
COX-2 was not stimulated in a time dependent manner at 6 h. mRNA and protein 
expression of COX-2 is shown.  (B) Compound 1F (EP4R Ag; 10 µM) did not significantly 
effect transcript expression of connexin-43 or interleukin-8.  Shown here are representative 




4.8 Summary and discussion  The EP4 receptor was originally described to couple with Gαs protein [132].  Recent data also extends EP4 receptor G protein‐coupling to include Gαi protein and also β‐arrestin  signalling  mechanisms.    There  is  currently  no  data  available  on  the activation of EP4 receptor in the myometrium.  Thus, this study describes the effects of a novel EP4 receptor agonist, Compound 1F, to investigate its potential role as a therapeutic target in preterm labour.  Initial  studies  focussed  on  the  expression  of  EP4  receptor  in  the  pregnant  and labouring myometrium.    Results  indicate  no  regulation with  labour  status,  or  any regional  difference  to  occur  at  the  onset  of  labour  for  EP4  receptor  protein  and mRNA.    This  agrees  with  semi‐quantitative  mRNA  and  non‐quantitative immunohistochemsitry  data  by  Astle  et  al  [97].    Grigsby  et  al  [99]  produced quantitative  mRNA  data  but  non‐quantitative  immunohistochemical  data.    Both groups  saw  no  regulation.    Using  quantitative  immunofluoresence  analysis  and quantitative  RTQ‐PCR  in  the  same  sample  set,  our  results  confirm  these observations.    There was a change in localisation of the EP4 receptor with the onset of labour from a  predominately  cytosolic presence  to  a more  defined  peri‐nuclear  location.    This shift in localisation of EP4 receptor, with the onset of labour, has also been noted by Grigsby  et  al  [99].    Nuclear  localisation  of  EP4  receptors  has  been  described previously in porcine cerebral microvascalar endothelial cells but no functional data was produced [156].  The role of peri‐nuclear EP4 receptors in myocytes is yet to be identified but may  suggest  it  is  an  important part of  the  labour process  since EP4 receptor peri‐nuclear  localisation  increases  in  labouring myometrial samples.   The presence  of  peri‐nuclear  EP4  receptor  suggests  endoplasmic  reticulum  or  late endosomal localisation.  The location of EP4 receptors could impact on its behaviour such as desensitisation of G‐protein  signalling or even activation of non‐G‐protein signalling from internal compartments. 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There is also sparse information available on EP4 receptor activation and its role in contractility.    In  our  experiments,  Compound  1F  did  not  demonstrate  significant changes  in  the  four  parameters  that  are  a  measure  of  contractility.    However, analysis of  total work done showed Compound 1F to significantly decrease rate of contractility  in  spontaneously  contracting myometrial  strips  at  10‐6 M.    This may sugggest  that EP4 receptor  in myometrium is coupled to Gαs proteins to cause an increase  in  adenylyl  cyclase  activity  and  therefore  cAMP  formation.    However, experiments  with  Compound  1F  on  cAMP  production  in  primary  cultures  of myocytes were not convincing.  cAMP levels were not significantly increased above or below non‐treated cell levels.    The apparent lack of robust EP4 receptor coupling to Gαs proteins may be due to its rapid desensitisation.   Prior studies comparing the ability of EP4 and EP2 receptor to  activate  cAMP  demonstrate  distinct  receptor  differences  in  HEK  293  cells.  Although PGE2 has a greater affinity for the EP4 receptor (EC50 = 2.8 nM) than the EP2 receptor (EC50 = 19 nM), PGE2 treatment induced ~71 fold increase in cAMP in EP2 expressing cells while only a ~10 fold increase in EP4 expressing cells [132].  If this  is  the  case  in myocytes,  then  the  stimulation  of  cAMP may  not  be  detectable since  EP2  receptor  activation was  only  able  to  induce ~1.5  fold  increase  in  cAMP (Chapter three).  To date, there is no other published data available on EP4 receptor activation  and  cAMP  generation.    Thus  further  experiments would  be  required  to look at possible mechanism of reduced cAMP / desensitisation, for example, analysis of β‐arrestin coupling, GRKs, etc.  Calcium mobilisation via EP4 receptor activation has been described in a previous study  where  mice  with  an  EP4  receptor  homozygous  deletion  were  unable  to increase  calcium  in  the  calvariae  (dome of  skull) of  fetal mice  [157].   The  calcium kinetics  induced by Compound 1F appears  to  be delayed and  longer  lasting when making comparisons with EP2 receptor activation.  However, in the presence of PTX, 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there  was  a  30  %  reduction  in  Compound  1F  treatment  and  the  calcium  profile response  is  altered.    This  does  not  suggest  full  Gαq  coupling  of  Compound  1F activated EP4 receptor but also Gαi mediated  coupling to some extent, possibly  to activate ion channels and influx of extracellular calcium for the latter.    Fujino et al [149] propose that an alternative target of EP4 receptor activation is PI3 kinase.    Upon  stimulation,  PI3  kinase  can,  either,  activate  ERK  leading  to  EGR‐1 induction  and  consequently  increase  in  cyclin  D1,  TNFα  and  PGE2  synthase synthesis.  Or, inhibit Akt kinase, which phosphorylates and inactivates GSK‐3β.  As GSK‐3β  can no longer  inhibit β‐catenin, β‐catenin can accumulate  in the cytoplasm and subsequently translocate to the nucleus.  Once in the nucleus, β‐catenin binds to Tcf/Lef transcription factor motifs to induce COX‐2 expression.  The data produced here does not  fully  support a  role  for Compound 1F  in  complete activation of  this pathway.  The small increase in cyclin D1 that is seen in some patient sample sets is not  as  a  consequence  of  EGR‐1  activation  but  maybe  in  part  because  of  ERK phosphorylation as seen in other cellular systems [158].  Regardless, any changes in cyclin D1 upon Compound 1F treatment did not effect the cell cycle.  When  assessed  by  immunofluoresence,  small  cellular  changes  of  β‐catenin expression  in  nuclear  and  cytosolic  compartments  could  be  seen;  nuclear localisation  of  β‐catenin  at  15  min  and  accumulation  in  the  cytosol  at  6  h.    The changes  in  β‐catenin  when  observed  by  Western  blotting  were  not  so  clearly defined.  This may be due to patient variability since the same patient sets were not used for both techniques.   However, these changes did not act further downstream on COX‐2 synthesis or other related pro‐inflammatory proteins such as connexin‐43.  IL‐8 mRNA did show an increase over time but this change was not significant.   Overall,  this  study  demonstrates  calcium  mobilisation  and  ERK  phosphorylation with  the  EP4  receptor  agonist,  Compound  1F,  however  no  target  protein  was identified  in  this  study.   Whether  Compound  1F  is  a  full,  partial  or  biased  ligand 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labour  In order to determine whether the EP1 or EP3 receptor expression is regulated by  labour  status  myometrial  biopsies  were  taken  from women  at  the  time  of Caesarean section, before and after  the onset of  labour.   Simultaneous biopsies were  taken  from  the  upper  and  lower  segment margins.    Tissue was  paraffin‐embedded  for  immunofluorescence  studies  and  protein  extracted  for Western blotting.  RNA was also isolated from tissue biopsies.    RTQ‐PCR  expression  studies  for  the  EP1  receptor  show  that  receptor  levels increase  in  the  lower  segment  at  the  time  of  labour  but  the  change  is  not significant (p = 0.08).   Expression in the upper segment is unaffected by labour status  (p = 0.79).   Western blotting of EP1  in  lower  segment myometrium was less  than  that  of  upper  segment  but  there  was  no  effect  of  labour  status  on abundance  in  the  groups.    Assessment  of  EP1  receptor  by  immunofluoresence demonstrates expression to not be significantly affected by  labour status  in  the upper  segment  myometrium  (p  =  0.66).    In  the  lower  segment  there  is  a significant  increase  in  the  mean  of  labouring  samples  compared  to  the  non‐labouring myometrium (p = 0.05) (Fig. 5.1).  Overall, there is an increase of EP1 receptor expression in the lower segment at the time of labour.       FIGURE 5.1 (see over) EP1 receptor is present in both pre and labouring myometrial tissue samples, upper and lower segment  (A) EP1 receptor expression was compared in matched lower (LS) and 
upper segments (US) of term labouring (L+) and term non-labouring (L-) myometrium.  mRNA was 
extracted and subjected to RTQ-PCR.  The housekeeping gene GAPDH was used to quantify the 
relative abundance of the EP1 receptor.  Mean is SEM± of 5 L- and 6 L+ independent samples.  SEM± 
is indicated with an error bar.  A Mann-Whitney test was applied and found differences to be non-
significant in all sample groups.  Protein was examined in whole cell tissue extracts. (B) Tissue was 
paraffin-embedded and (i) the specificity of the antibody determined by using immunohistochemsitry 
with polyclonal EP1 antibodies.  Replacement of anti-EP1 antibodies with preimmune IgG (IgG) and 
saturation of anti-EP1 antibodies with blocking peptides (BP) were used as negative controls.  (ii) 
immunofluorescent analysis for EP1 was visualized with red-fluorescent Alexa Fluor 594 dye, and α-
actin was visualized with green-fluorescent Alexa Fluor 488 dye.  Nuclei was stained with DAPI.  All 
images were captured with a x40 objective.  (iii) Intensity of receptor expression was analysed by 
measuring level of fluorescence and applying statistical analysis.  These graphs represent the intensity 
of expression of EP1 receptor in the cytosol of myocytes.  The p value is from Mann-Whitney test. (C) 
Lysates were subjected to Western blotting and blots were scanned for densitometric analysis.  










Figure 5.2.  Arrows depict nuclear presence of EP1 receptor in labouring myometrium (L+) versus 
non-labouring myometrium (L-).  Immunofluorescent analysis of EP1 receptor was visualised with 
red-fluorescent Alexa Fluor 594 dye.  Nuclei was stained with DAPI.  Images were captured with a 
x40 objective.  Intensity of receptor expression was analysed by measuring level of fluorescence in 
the nuclei and applying statistical analysis.  The graphs represent the intensity of expression of 
EP1 receptor in the nuclei of myocytes.  The p value is from a Mann-Whitney.  Results are the 




at the time of labour  RTQ‐PCR was also conducted for EP3 receptor variants.  EP3 primer design was based  upon  Figure  5.3,  which  depicts  the  variants  and  the  respective  exons present.   All EP3 variants were present  in a non‐pregnant uterus  control  (data not  shown).    Interestingly when analysis was  done  in pregnant  samples,  i.e.  in pre‐labour  status,  EP3  variants  ‐1,  ‐2,  ‐3  and  ‐4 were  absent.    At  the  onset  of labour, a small increase was seen in the expression of these variants, particularly ‐1 and ‐4, but the changes were less than two fold (Fig. 5.4).    
     Excluding  variant  EP3‐6  in  the  lower  segment,  before  the  onset  of  labour,  the remaining  variants  are  present  before  the  onset  of  labour  in  both  upper  and lower segment sample groups.  There is a nominal increase of EP3‐5 at the time of labour in the lower segment and a decrease in the upper segment at the time of  labour.   Transcripts EP3‐6, EP3‐7, EP3‐8 and EP3‐9 showed a collective, but not significant, increase in expression in the upper segment as compared to the lower segment at the time of labour.  EP3‐10 expression did not vary with labour status. (Fig. 5.5).   
Fig. 5.3.  EP3 variants and exon information.  Numbers (black print) represent 
annotations used in this thesis with the corresponding lettering (red print) used in 
literature.  All EP3 variants contain Exon 2. 
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 Figure 5.4.  RTQ-PCR analysis of EP3 receptor variants in pre and labouring myometrial 
tissue samples, upper and lower segment.  EP3 variant expression was compared in matched 
upper (US) and lower (LS) segments of lerm (L+) and term non-labouring (L-) myometrium.  
mRNA was extracted and subjected to RTQ-PCR.  The housekeeping gene GAPDH was used 
to quantify the relative abundance of each variant.  Mean is SEM± of 3 L- and 3 L+ 





Figure 5.5. RTQ-PCR analysis of EP3 receptor variants in pre and labouring myometrial tissue 
samples, upper and lower segment.  EP3 variant expression was compared in matched upper 
(US) and lower (LS) segments of term (L+) and term non-labouring (L-) myometrium.  mRNA 
was extracted and subjected to RTQ-PCR.  The housekeeping gene GAPDH was used to 
quantify the relative abundance of each variant.  Mean is SEM of 3 L- and 3 L+ independent 
samples.  SEM is indicated with an error bar.  A Mann-Whitney test was applied.  There is no p-
value above LS EP3-6 (ψ)  since transcripts are absent from non-labouring tissue and so 




  FIGURE 5.6.  EP3 receptor is present in both pre and labouring myometrial tissue samples and in 
upper and lower segment.  (A) EP3 receptor expression was compared in matched lower (LS) and 
upper segments (US) of term labouring (L+) and term non-labouring (L-) myometrium.  Protein was 
examined in whole tissue extracts. (B) Tissue was paraffin-embedded and (i) the specificity of the 
antibody determined by using immunohistochemsitry with polyclonal EP3 antibodies.  Replacement of 
anti-EP3 antibodies with preimmune IgG (IgG) and saturation of anti-EP3 antibodies with blocking 
peptides (BP) were used as negative controls.  (ii) immunofluorescent analysis for EP3 was visualized 
with rabbit anti-EP3 antibody with Alexa Fluor 594 conjugated secondary antibody (red), and α-actin 
was visualized with mouse anti-actin antibody with Alexa Fluor 488 conjugated secondary antibody 
(green).  Nuclei were stained with DAPI.  All images were captured with a x40 objective.  (iii) Intensity 
of receptor expression was analysed by measuring level of fluorescence and applying statistical 
analysis.  These graphs represent the intensity of expression of each PGE2 receptor in the cytosol of 
myocytes.  The p value is from a non-parametric test (Mann-Whitney). (C) Lysates were subjected to 
Western blotting and blots were scanned for densitometric analysis.  Results are the mean of 5 L- and 








      Figure 5.7. Effect of EP1 receptor antagonist on spontaneously contracting myometrial strips.  Myometrial strips were mounted onto the DMT myograph and stretched at 4 g tension.  
Spontaneous contractions were established after 90 min and agonist was added in log doses at 
20 min intervals.  Control chambers with equivalent volumes of vehicle control were run 
simultaneously (n=3).  Any strips that did not spontaneously contract within 90 min of the 
experiment were excluded from analysis.  An ANOVA was performed along with the Bonferroni 
correction.  PGE2 induced a significant increase of total work done versus control strips 
(indicated with an *).  The EP1 receptor antagonist had no significant effect on PGE2 treated 




          Figure 5.8. Effect of EP3 receptor antagonist on spontaneously contracting myometrial strips.  Myometrial strips were mounted onto the DMT myograph and stretched at 4 g tension.  
Spontaneous contractions were established after 90 min and agonist was added in log doses 
at 20 min intervals.  Control chambers with equivalent volumes of vehicle control were run 
simultaneously (n=3).  Any strips that did not spontaneously contract within 90 min of the 
experiment were excluded from analysis.  An ANOVA was performed along with the 
Bonferroni correction.  PGE2 induced a significant increase of total work done versus control 
strips.  The EP3 receptor antagonist was able to significantly inhibit PGE2 treated strips as 
indicated by * .   
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 Figure 5.9.  Calcium mobilisation in the presence of an EP3 agonist.  Confluent, prelabour, 
myocytes were serum starved overnight.  They were then loaded with Fluo-4 and visualised 
with a Leica confocal microscope.  Cells treated with EP3 agonist (10 µM) show an increase in 
calcium mobilisation that was (A) ablated in presence of BAPTA-AM and to (B) decrease in the 
presence of PTX pre-incubation.  A representative experiment is shown.  (n =  3).   
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Figure 5.10.  EP3 receptor agonist (EP3R Ag.) causes inhibition of adenyly cyclase and 
cAMP formation.  Primary cell cultures were pretreated with IBMX for 5 min and incubated 
with EP3R Ag. (10 µM) for 30 min.  To test Gαi coupling, primary cultures were pre-treated 
with PTX overnight (200 ng/mL) and treated with IBMX for 5 min.  Cells were then applied 
with EP3 receptor agoinist for 30 min.  The experiment was terminated and lysed with 0.1 % 
HCl / Triton X-100.  cAMP was measured using an EIA system.  A representative 
experiment is shown (n = 3). 
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 Figure 5.11.  Deglycosylation of whole myometrial tissue lysate.  Pre-labour tissue lysate (100 
µg) was incubated with and without PNGaseF (15 milliunits) for 3 h and 24 h to observe the 
extent of deglycosylation.  Protein was measured and run on a 12 % SDS-PAGE.  
Immunoblotting with EP3 antibody revealed there to be deglycosylation of a band at 
approximately 100 kD to approximately 80 kD.  (A) Arrows indicate the drop between the two 
sizes (B) Arrows indicate diffuse band to be four distinct species after deglycosylation. 
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Figure 5.12.  Silencing of EP3 variant 9 indicate it to be part of a homo/hetro/oligo dimer in 
whole cell myocytes.  Cells were treated with si variant 9 for 96 h.  Control cells were treated 
with non-targeting (NT) siRNA.  Whole cell protein was extracted and run by SDS-PAGE.  
Membranes were immunoblotted with EP3 antibody and show there to be silencing of a band 
at approximately 80 kD.  Arrows indicate all EP3 bands present in whole cell tissue. 
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5.8 Summary and discussion  At  the  time  of  labour,  EP1  and  EP3  receptors  are  assumed  to  contribute  to promoting contractions in the myometrium due to their respective coupling of both Gαq/11  and  Gαi  proteins.    Expression  data  presented  here  shows  significantly higher levels of EP1 receptor protein in the lower segment when analysis is done by immunofluoresence, although, this change is not reflected in Western analysis.  This disparity  between  techniques  may  be  due  to  immunofluoresence  detecting  EP1 receptor  in  its  native  form.    A  protein,  particularly  GPCRs,  will  often  not  just  be present  at  the  plasma  membrane  but  intracellularly  in  the  ER,  and  even  as homodimers,  oligomers,  etc  and  immunfluorescent  staining  would  pick  up  all  of these forms, whereas the Western blotting, since it is a reducing gel, may only pick up the presence of monomers and therefore not be reflective of total EP1 receptor expression.   mRNA levels are also elevated in the lower segment but the change is not significant.  These findings agree with data from Astle et al [97] and Grigsby et al [99] who also found EP1 mRNA levels to increase significantly in the lower segment.    Additional immunofluorescence analysis focused on the nuclear compartment and it was  found  that  EP1  receptor  was  predominately  expressed  in  the  nuclei  of labouring myocytes,  in both upper and  lower segment.   The expression of nuclear EP1 protein was also noted by Astle et al [97] in their pro‐labour sample group, but with  quantitative  analysis  of  immunofluorescent  staining we  are  able  to  say with confidence  that  this  change  is  significant.    Nuclear  localised  GPCRs  have  been reported  for more  than 15 years, but  remain  contentious primarily due  to  lack of mechanistic  and  physiological  understanding.    In  addition  to  GPCRs,  there  are reports of components of the PGE2 biosynthetic pathway being present in the nuclei –  for  example  COX‐2  [165]  phospholipase‐A2  [166],  and  various G‐proteins  [167].  Prostaglandins can also be pumped into the intracellular space by the prostaglandin transporter  [168]  to  act  on  nuclear  receptors.    In  terms  of  PGE2  receptor, Bhattacharya  et  al  [156]  used  isolated  nuclei  of  porcine  cerebral  microvascular 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endotheilial cells (PCEC) and transfected hamster embryonic kidney (HEK) 293 cells to  show  nuclear  expression  of  EP3  and  EP4  receptors.    Functionality  of  the  EP3 receptor  was  confirmed  in  isolated  nuclei  with  the  use  of  an  EP3  agonist,  which increased gene transcription of nitric oxide and mobilised calcium [169, 170].  Since none  of  the  EP  receptors  contain  a  nuclear  localisation  domain,  it  has  been postulated  that  this  could  imply  endocytosis  and  nuclear  translocation  of  plasma membrane‐liganded EP receptors or post‐translational modifications.   The  re‐localisation  of  EP1  receptor  to  the  nucleus,  in  labouring  myocytes,  is intriguing.  Other published data on nuclear EP receptors is beginning to identify the presence  of  nuclear  EP1  receptor  as  an  important  marker  of  breast  cancer prognosis.    Thorat  et  al  [171]  examined  normal  and  abnormal  breast  cancer  cell lines  and EP1 nuclear  staining  correlated with  good prognostic markers  of  breast cancer,  specifically,  progesterone  receptor  expression  and  nodal  status.    Ma  et  al [172]  extended  these  observations  with  analysis  of  human  biopsies  of  invasive ductal carcinomas with immunohistochemistry and found it was those with nuclear EP1  that went  onto  have  a more  positive  prognosis  than  those  that were  lacking nuclear  EP1  expression.   However,  this  is  a  pathophysiological  setting where  EP1 receptor  is presumably  responding  to a dysregulated environment.    Labour  is not pathophysiological  however,  and  nuclear  EP1  receptor  expression  at  the  time  of labour and the role of this apparent translocation is yet to be discovered.  However, since EP1 antagonists could not inhibit contractility, nuclear EP1 expression may be where EP1 receptor activity is at its most critical at labour; EP1 receptor couples to Gαq/11  proteins  and  therefore  calcium  mobilisation.    Calcium  is  necessary  for activation  of  transcription  factors,  thus  the  role  of  EP1  receptor  at  parturition maybe  to  increase  intra‐nuclear  calcium,  from  calcium  pools  on  the  nuclear envelope,  thereby  regulating  pro‐labour  genes.    Future  experiments  would therefore benefit by concentrating on this nuclear presence of EP1 receptor and also to examine contractility and the effects of EP1 antagonist on labouring myocytes. 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EP3  receptor  transcripts  are  present  for  all  variants  in myometrial  biopsies.    The transcripts  vary  in  expression  levels,  however,  the  low  level  of  expression  of variants EP3‐1, ‐2, and ‐3 is in line with them being classified as non‐coding mRNA, due  to  the  use  of  a  5’  –most  supported  translational  codon,  which  renders  the transcripts as candidates for nonsense mediated mRNA decay.  There is an increase in  labouring  samples  of  their  transcript  levels  but  the  likelihood  of  these  being translated  into protein are  low.   EP3‐4 and EP3‐10 mRNA is also expressed at  low levels relative to the other transcripts.  However, variants EP3‐4, ‐9 and ‐10 encode the same protein so the relevance of this may not be significant.    Apart  from variant EP3‐5,  there  is a general  trend for an  increase  in expression of the  remaining EP3  isoforms with  the  onset  of  labour  (Fig.  5.5).    In Grigsby  et  al’s sample  set  [99]  there  is  a  significant  increase  in  EP3  receptor  transcripts  in  the upper segment only, but the transcript information retrieved was for that of all EP3 variants  –  i.e.  reverse  primers  were  designed  before  the  splice  site,  and  not  for individual isoforms.  Conversely Astle et al [97] found total EP3 receptor to decrease with labour in the lower segment.  If the variant expression levels from our results were  collated,  it  would  show  transcripts  to  be  up‐regulated  mainly  in  the  upper segment at  the time of  labour and therefore would agree with the observations of Grigsby et al [99].    The  difference  between  the  activity  and  regulation  of  the  EP3  variants  has  been summarised  in  Table  5.2.  It  includes  their  respective  constitutive  activity  and  the potential  for sustained β‐arrestin association.   This  list does not describe the non‐coding mRNA variants. 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Activity [174]  










EP3 III 7 No internalisation Yes 
EP3 IV 6 No internalisation Yes 
EP3 E 8 Unknown Unknown   Of the variants present in pregnancy, EP3‐9 and EP3‐5 are the most similar in terms of activity.  However, EP3‐9 increases in the in‐labour samples.  The significance of increased EP3‐9 transcript may be pinpointed to its C‐terminal sequence, which has two serine/threonine clusters.   These are potential sites for determining sustained association with β‐arrestin.  EP3‐5 does not internalise with β‐arrestin and isoforms EP3‐7  and  EP‐6  (no  information  available  fore  EP3‐8)  do  not  have  these  clusters [173].  β‐arrestin is crucial in the regulation of GPCR trafficking and termination of signalling cascades; it is now also accepted that it plays a primary role in G‐protein‐independent  signalling,  specifically  acting  as  a  scaffold  protein  to  link  receptor activation  to  a  variety  of  signalling  cascades  [175].    Rapid  internalisation  of  a receptor would  also  effect  the  kinetics  of  its  response;  EP3‐9  internalises  rapidly and this could be an arrest of cell signalling and recycling of the receptor or EP3‐9 could continue to signal intracellularly.    Jin  et  al  [174]  investigated  the  constitutive  activity  of  the  EP3  isoforms  and demonstrated EP3‐5 and EP3‐9 to be constitutively inactive in the absence of ligand in CHO‐K1 cells.   Taking  into consideration the constitutive activity variation of all EP3 isoforms, it could be postulated that the reason for having many EP3 isoforms, 
Table 5.2.  EP3 variant information. 
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present in the prelabour uterus, is that there becomes a state of balance when all are expressed; EP3‐7 and EP‐6 were found to be constitutively active in these cells (this activity was  sensitive  to PTX) and  therefore  could play more homeostatic  roles  in myocytes or to regulate the activity of the constitutively active isoforms.  Therefore, it  is  the  altering  of  the  constitutively  inactive  isoform,  EP3‐9,  that  would  most impact  on  cell  signalling  in  the  pregnant  myometrium,  thereby  becoming  the labouring myometrium.    The protein expression of EP3 receptor did not significantly change when analysed with  Western  blotting.    Immunofluoresence  analysis,  on  the  other  hand,  showed there  to  be  an  increase  in  the  expression  of  EP3  in  the  cytosol  of  the  labouring myometrium, from the lower segment.  Commenting on these differences is difficult since  the  antibody  used  to  detect  EP3  receptor  expression was  raised  against  an epitope that detects all EP3 variants – i.e. before the splice site.  In the Western blot there  are  four  bands  seen  around  55  kD  size.    Some  of  the  splicing  products translate into the same sized protein also making it impossible to determine which variants  are  being  expressed  although  the  mRNA  data  indicates  that  it  is  most probably EP3 5, ‐6, ‐7 and ‐8 whilst the silencing of EP3‐9 demonstrates it to be part of  a  higher dimer.    Additionally, Western  blotting  analysis was  carried  out  on  the three bands together, as it was not possible to run out the bands enough in order to analyse each band separately.   This could potentially explain why detection of EP3 receptor  varies  when  studied  by  immunofluorescence  but  not  with  Western blotting.    However,  the  immunofluoresence  results  still  leave  us  in  the  position where it is not known which variant is being dominantly expressed.  Although, if the mRNA data and protein data were tied together it would appear that it is EP3‐9 that is raised not only in transcript levels in the lower segment but protein expression as well.  Activation of EP3 receptor resulted  in a decrease  in cAMP and  increase of calcium responses.  PTX was unable to inhibit this response, which implies that perhaps EP3 agonist  is  activating  other mechanisms  to  release  calcium.    EP3  receptor  variants 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Parturition marks  the  end  of  pregnancy.    It  is  the  accumulation  of  changes  in  the myometrium, which remodels itself from a non‐synchronous entity to a networked system  that  is  able  to  generate  co‐ordinated  contractions  to  expel  the  foetus.  However, parturition does not always occur in a timely manner; preterm births are prevalent in 10 % of pregnancies and pose a major health risk in the undeveloped neonate.  Although care of the premature neonate has improved the rate of preterm labour  shows no  sign of  abating.   Contractility  is  considered  to be mechanistically the same in term and preterm labour.  Therefore it is research into the physiological pathways  that  modulate  the  activity  of  contractions  that  will  provide  an understanding about the pathological disease and consequently the development of tocolytics to be used in the clinic.  It is proposed that the pregnant myometrium is divided into two regions; the upper and  lower  segments.    These  regions  are  said  to  differ  in  contractile  activity;  the upper  segment  is  quiescent  during  pregnancy  and  the  lower  segment  exhibits contractures of  low  frequency  throughout pregnancy but  these  are  suppressed by the hormonal milieu.  At the onset of labour there is a switch of activity between the regions  with  the  fundal  region  contracting  frequently  and  forcefully  pushing  the neonate downwards, whilst the lower segment is now relaxed to allow the passing and movement of  the neonate outwards [177].   Studies  that support  this  theory of regionalisation have shown labour specific changes of proteins in the myometrium with this change extended to regional differences;  the upper segment containing a more  concentrated  expression  of  COX‐2,  connexin  43  [10],  and  oxytocin  receptor [13]  at  the  time  of  labour.    However,  not  all  studies  support  this  model  of regionalisation;  Sooranna  et  al  [25]  and  Sparey  et  al  [10]  found  COX‐2  to  be significantly higher in the lower segment at the time of labour.  Contractility studies have also been conducted; Luckas et  al  [178] examined upper and  lower  segment tissue and found no difference in contractility responses.   Conversely, Wiqvist et al [179] found contractility to occur in the upper segment but not the lower segment.  Additionally, the spread of contractions does not differ dependent on where in the uterus  it  is monitored  [180].    This  also  does  not  support  the  theory of  functional 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regionalisation, which  postulates  that  contractions  begin  in  the  fundal  region  and spread  downwards.    This  is  supported  by  the  absence  of  pace  maker  activity  in myocytes [7], which would dictate the origin and direction of a wave.  Since there is no pace maker activity, and no origin, then a contraction could feasibly begin from any point.      Prostaglandins  have  been  identified  as  crucial  mediators  of  parturition.  They  are produced  by  catalysation  of  arachidonic  acid  by  COX  synthesizing  first  PGG2  and then PGH2.  PGH2 is acted upon by cell specific synthases to produce prostaglandins.  Prostaglandin  E2  (PGE2)  is  synthesised  via  prostaglandin  E  synthase.    The importance  of  PGE2  in  labour  is well  established;  its  synthesis  is  seen  to  increase incrementally  with  increasing  gestation  by  the  fetal  membranes  [22,  23]  and application  to  myometrial  strips  in  our  hands  causes  an  increase  in  duration, frequency  and  peak  tension  of  contractions,  resulting  in  a  significant  increase  in total  work  done,  for  both  upper  and  lower  segment  biopsies.    This  contradicts  a study that found PGE2 to cause a decrease in contractions [181] and another study that found application of PGE2 to stimulate contractions in only the upper segment and  not  the  lower  segment  of  the  labouring  myometrium  [179].    However,  the general mass of data suggests a physiological role in facilitating contractions at the time of labour.  PGE2  is  a  hormone  capable  of  commanding  a vast  array  of  responses  in most  cell types.   This is due to the presence of four receptors, termed E series prostaglandin receptors  (EP1  –  EP4),  which  bind  PGE2  with  varying  efficacies  but  ultimately modulate a dynamic profile of responses.  The receptors are able to do this through their coupling of specific G‐proteins.  In vivo, PGE2 is unstable with a chemical half‐life  of  30  s  and  is  rapidly  metabolised  to  13,14‐dihydro‐15‐keto  PGE2  [28], reinforcing the importance of cell surface expression of EP receptors and their role in  relaying  PGE2  binding.    Until  now,  the  literature  has  only  been  able  to demonstrate  expression  of  EP‐transcripts,  in  upper  and  lower  segment myometrium, with protein expression only seen via immunohistochemistry [97, 99]. 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Additionally,  there  is  a  limited  amount  of  information  on  EP  receptors  and  the downstream mechanisms attached  to  their  activation  in  the myometrium.   Data  is only  available  from  non‐pregnant  myocytes  [92,  131]  and  therefore  cannot  be applied  to  how  a  pregnant  phenotype  would  respond  and  thus  should  be approached  with  caution.    For  instance,  Wang  et  al  [182]  studied  the  effects  of calcium on potassium currents in rat non‐pregnant and late‐pregnant myocytes and found  difference  in  relative  amplitudes,  and  calcium  dependence  amongst  other factors to vary between the cell types.    The general trend of expression of EP receptors in our sample set does not support the theory that regionalisation is based on an upper segment being contractile at the time  of  labour or  that  the  lower  segment  functions  to  relax  at  the  time  of  labour.  Whilst EP1 and EP3 protein, via immunofluoresence and RTQ‐PCR analysis, increase significantly  in  the  lower  segment,  the  Western  protein  data  does  not  strongly support an increase in expression of these receptors.  EP2 and EP4 also do not vary significantly  between  regions  at  the  time  of  labour.    Based  on  the  model  of regionalisation  the  relevance  of  this  expression,  physiologically,  is  difficult  to comment upon.   However,  and most  importantly,  this  is  based on  the assumption that  EP1  and  EP3  receptors  are  contractile  and  that  EP2  and  EP4  receptor  are relaxatory in the uterus.   Early signalling studies, usually in recombinant cell lines, have  been  assumed  to  be  the  norm  in  human  cells.    However, what  is  becoming apparent  and  equally  of  importance,  is  the  promiscuous  binding  of  GPCRs  to  G proteins.   Studies presented here demonstrate EP2 receptor activation to inhibit contractility in tissue.  However, in a monolayer of cells, EP2 receptor agonist was able to induce the expression of the rate‐limiting step in its ligand synthesis, COX‐2.  This was over the  course of  six hours.    So, whilst  short  term EP2  receptor activation  relaxes  the myometrium, long‐term activation shows that COX‐2 would also be activated.  Since EP2  receptor agonists were applied  to  spontaneous  contracting myometrial  strips over  the  course  of  under  two  hours  it  could  be  possible  that  had  contractility 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experiments been extended, COX‐2 production would have increased and lead to an increase  in  contractility.    This  concept  is  supported  by  studies  conducted  by Fetalvero  et  al  [183];  activation  of  prostacylcin  receptors  (IP),  which  are  Gαs coupled  and  therefore  increase  cAMP  formation,  lead  to  an  increase  of  pro‐contractile proteins (gap junction and contractile proteins) after a six hour stimulus.  Incubation  of  pregnant myometrial  strips  for  48  hours,  with  IP  receptor  agonist, caused  enhanced  contractility  in  response  to  oxytocin.    Additionally,  we demonstrate a novel‐signalling pathway of EP2 receptor activation in the induction of COX‐2 in the myometrium.  Traditional EP2 receptor coupling, from early studies in cell lines, concluded that EP2 receptor couple to Gαs protein.  We show here that EP2 receptor activation also mobilises calcium to induce COX‐2.    The novel EP4 agonist used  in  this  study, Compound 1F, did not  strongly activate any specific cell‐signalling pathway.  Therefore it is difficult to generalise on the role of  EP4  receptor  at  the  time  of  labour.    However,  EP4  receptor  expression localisation at  the peri‐nuclear  region,  at  the  time of  labour,  is  indicative of ER or late  endosomal  retention.    This  could  be  due  to  the  rapid  internalisation  of  EP4 receptor and hence recycling back to the cell surface [96] or perhaps EP4 receptor could initiate signalling within the internal compartments via β‐arrestin association [175].   Overall,  the role of EP4 receptor needs further clarification, perhaps with a panel  of  EP4  receptor  agonists  to  gain  a  better  understanding  of  the  role  of  EP4 receptors  in  the  uterus,  since  it  may  be  that  Compound  1F  is  not  a  good representation of EP4 receptor activation in the myometrium [152].    It  has  also  been  demonstrated  here  that  EP3  receptors  modulate  the  contractile phenotype greater than EP1 receptor; EP1 antagonists failed to inhibit spontaneous and PGE2 induced contractility.   Although EP1 expression increased significantly in the  lower  segment,  as well  as  a  significant  increase  in  nuclear  localisation  of  EP1 receptor  in  both  upper  and  lower  segment  at  the  time  of  labour,  this  did  not translate  into a  functional contractile mechanism.   However, our studies examined 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contractility  in  pre‐labour  samples,  therefore  it  is  possible  that  EP1  receptor antagonist  may  have  modulated  activity  of  in‐labour  myometrial  strips.    EP3 receptor variant expression increased with labour in both upper and lower segment samples,  alongside  generic  EP3  receptor  immunofluorescent  expression  in  the lower  segment.    EP3  antagonists  also  inhibited  spontaneously  and  PGE2  induced contractions.    Cell  signalling  experiments  indicate  that  this  may  be  due  to  the coupling of EP3 receptor variants to Gαq/11 and Gαi proteins.          Overall, PGE2 increased contractility of spontaneously contracting tissue.   Although this  is  an  in  vitro  environment  it  suggests  that  in  the  myometrium,  when  all  EP subtypes are present, ligand binding activates the contractile phenotype.  This may then be extended to the maternal in vivo environment where increased synthesis of PGE2 by fetal membranes at the time of labour act on the myometrium and lead to the initiation of parturition.    Using a systems biology approach, it must be remembered that the hormonal milieu is  complex  and  that  the myometrium  is  a  heterogenous  organ with many  labour associated proteins that have been identified.  It is likely that cross‐talk is happening across  the  spectrum  and  not  due  to  lone  signals  leading  to  individual  pathway activation.   Many  pathways  probably  lead  to myometrial  activation  and  therefore parturition.    This  may  help  explain  why  current  tocolytics  are  failing  to  delay contractions for more than 48 hours.  Perhaps, then, a multi‐target therapy strategy ought be considered.   This could be the antagonising of EP2 and EP3 receptors as detailed in this thesis.    In  conclusion,  EP2  receptors  may  not  be  a  suitable  tocolytic  target  for  the prevention of preterm labour.  The role of EP1 and EP4 receptor activation remains to  be  further  investigated.    EP3  receptor  antagonists  significantly  inhibited contractility and therefore appear to be a potential tocolytic target.   However, EP3 receptors  also  carry  out  functions  in  other  organs  (Kidney  [184],  lung  [185], 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myometrial biopsies                         FIGURE 7.0.1. Example EP2 receptor myograph traces.  Pre-labour myometrial tissue biopsies were 
mounted and connected to the Myograph DT system.  Tissue was stretched at 4 g tension and 
spontaneous contractions established after 90 min.  Agonist was added at 20 min intervals.  Control 
chambers with equivalent volumes of vehicle control were also run simultaneously.  Tissue viability was 




myometrial biopsies                               FIGURE 7.0.2. Example EP4 receptor myograph traces.  Pre-labour myometrial tissue biopsies were 
mounted and connected to the Myograph DT system.  Tissue was stretched at 4 g tension and 
spontaneous contractions established after 90 min.  Agonist was added at 20 min intervals.  Control 
chambers with equivalent volumes of vehicle control were also run simultaneously.  Tissue viability 





    FIGURE 7.1.0. Nuclear localisation analysis of EP receptors in pre and post labour myometrial 
tissue samples. Intensity of receptor expression was analysed by measuring level of 
fluorescence and applying statistical analysis.  These graphs represent the intensity of 
expression of EP receptors in the nuclei of myocytes.  The p value is from Mann-Whitney test.      
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